

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 November 2006 (30.11.2006)

PCT

(10) International Publication Number  
**WO 2006/125983 A1**

(51) International Patent Classification:

C07K 14/02 (2006.01) A61K 48/00 (2006.01)  
C12N 15/85 (2006.01) A61K 39/285 (2006.01)  
C12N 15/863 (2006.01)

[GB/GB]; Oxxon Therapeutics Ltd, 2nd Floor Florey House, 3 Robert Robinson Avenue, The Oxford Science Park, Oxford Oxfordshire OX4 4GP (GB).

(21) International Application Number:

PCT/GB2006/001902

(74) Agents: KING, Hilary et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(22) International Filing Date: 23 May 2006 (23.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/683,877 23 May 2005 (23.05.2005) US  
0515439.8 27 July 2005 (27.07.2005) GB  
60/782,710 15 March 2006 (15.03.2006) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): OXXON THERAPEUTICS LTD [GB/GB]; 2nd Floor, Florey House, 3 Robert Robinson Avenue, The Oxford Science Park, Oxford Oxfordshire OX4 4GP (GB).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHNEIDER, Joerg [DE/GB]; Oxxon Therapeutics Ltd, 2nd Floor Florey House, 3 Robert Robinson Avenue, The Oxford Science Park, Oxford Oxfordshire OX4 4GP (GB). CHORLTON, James [GB/GB]; 29 Grove Hill, Chalfont St Peter, Gerrards Cross Buckinghamshire SL9 9PE (GB). PEARCE, Gill [GB/GB]; Dial Close Cottage, Winter Hill, Cookham Dean, Maidenhead Buckinghamshire SL6 9TT (GB). JONES, Nicola [GB/GB]; Charles River Laboratories, Clinical Europe-Asia Pacific Locations, Maidenhead Buckinghamshire (GB). BROWN, Dean

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST HEPATITIS B

(57) Abstract: The present invention is directed to a method of inducing an immune response against a hepatitis B antigen (e.g., an antigen from a hepatitis B virus) in a mammal, which comprises administering to the mammal a priming composition (e.g., a DNA plasmid), comprising a source of one or more epitopes of the hepatitis B target antigen; and a boosting composition, comprising a source of one or more epitopes of the hepatitis B target antigen (e.g., a non-replication or replication-impaired poxvirus such as MVA), wherein at least one epitope of the boosting composition is identical to an epitope of the priming composition. The present invention also is directed to a method of inducing an immune response against a hepatitis B antigen (e.g., an antigen from a hepatitis B virus) in a mammal, which comprises administering to the mammal a priming composition (e.g., a DNA plasmid), comprising a source of one or more epitopes of the hepatitis B target antigen. In addition, the present invention is directed to compositions for use in the methods of the present invention.

WO 2006/125983 A1

B18

**Compositions for Inducing an Immune Response Against Hepatitis B**

Hepatitis B is caused by a 42 nm double-stranded DNA virus that is the prototype member of the hepadnavirus family. There are more than 350 million carriers of the hepatitis B virus (HBV) world-wide, and chronic active hepatitis leads to cirrhosis and  
5 hepatocellular carcinoma in approximately one quarter of these individuals.

A major problem in HBV immunotherapy has been the identification of a means of inducing a sufficiently strong immune response in individuals with chronic hepatitis B. A number of different immunisation strategies have failed to generate clinically-effective immune responses against the infection in humans.

10 There is a clear need for the development of improved methods for inducing an immune response to hepatitis B infection in an individual in need thereof.

The present invention encompasses a method of inducing an immune response against a (one or more) hepatitis B antigen (*e.g.*, an antigen from the hepatitis B virus) in a mammal (*e.g.*, human), which comprises administering to the mammal a priming  
15 composition (*e.g.*, a DNA plasmid) comprising a source of one or more epitopes of the hepatitis B antigen; and a boosting composition comprising a source of one or more epitopes of the hepatitis B antigen (*e.g.*, a non-replication or replication-impaired poxvirus such as MVA); wherein at least one epitope of the boosting composition is identical to an epitope of the priming composition.

20 In one embodiment, the source of one or more hepatitis B epitopes in the priming composition is a DNA plasmid (*e.g.*, pSG2.HBs). In another embodiment, the source of one or more hepatitis B epitopes in the priming composition is a viral vector, which is derived from a virus other than a non-replicating or replication-impaired poxvirus. In a further embodiment, the source of one or more hepatitis B epitopes is a non-replicating or  
25 replication impaired recombinant poxvirus; with the proviso that if the source of epitopes in the priming composition is a viral vector, the viral vector in the boosting composition is derived from a different virus. In a particular embodiment, the non-replicating or

replication-impaired recombinant poxvirus is a Modified Vaccinia Virus Ankara (MVA) (*e.g.*, MVA.HBs).

The present invention also encompasses a method of inducing an immune response against a (one or more) hepatitis B antigen (*e.g.*, an antigen from the hepatitis B virus) in a mammal (*e.g.*, human), which comprises administering to the mammal a priming composition (*e.g.*, a DNA plasmid) comprising a source of one or more epitopes of the hepatitis B antigen. In a particular embodiment, the source of one or more hepatitis B epitopes in the priming composition is a DNA plasmid that is capable of expressing a hepatitis B antigen in a mammal (*e.g.*, pSG2.HBs).

- 10 The present invention also includes an isolated plasmid comprising the nucleotide sequence of SEQ ID NO: 1. In addition, the invention provides an isolated recombinant replication-deficient poxvirus (*e.g.*, MVA) comprising an insert, which comprises the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 5. The invention also encompasses compositions comprising an isolated plasmid comprising the nucleotide sequence of SEQ ID NO: 1, and compositions comprising an isolated recombinant replication-deficient poxvirus (*e.g.*, MVA) comprising an insert, which comprises the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

In one aspect the invention is a method of inducing an immune response against hepatitis B in a subject comprising the steps of

- 20 a) administering to the subject a priming composition comprising a DNA plasmid comprising a nucleotide sequence that is at least 90% homologous or identical to SEQ ID NO: 4 or SEQ ID NO: 5 followed by
- b) administering to the subject a boosting composition comprising a recombinant MVA vector comprising a nucleotide sequence that is at least 90% homologous or identical to
- 25 SEQ ID NO: 4 or SEQ ID NO: 5

Also contemplated is a kit for inducing an immune response against hepatitis B in a subject comprising a) a priming composition comprising a DNA plasmid comprising a nucleotide sequence that is at least 90% homologous or identical to SEQ ID NO: 4 or SEQ ID NO: 5 and

b) a boosting composition comprising a recombinant MVA vector comprising a nucleotide sequence that is at least 90% homologous or identical to SEQ ID NO: 4 or SEQ ID NO: 5.

5 Also contemplated is the use of a) a priming composition comprising a DNA plasmid comprising a nucleotide sequence that is at least 90% homologous or identical to SEQ ID NO: 4 or SEQ ID NO: 5 and

b) a boosting composition comprising a recombinant MVA vector comprising a nucleotide sequence that is at least 90% homologous or identical to SEQ ID NO: 4 or SEQ ID NO: 5,

10 in the manufacture of a medicament for inducing an immune response against hepatitis B in a subject.

Preferably the DNA plasmid and/or the recombinant DNA vector comprise nucleotide sequence that is at least 95%, 98%, 99% or 100% homologous or identical to SEQ ID No4 or SEQ ID NO: 5

15 Preferably the subject is a primate, more preferably a human.

In one embodiment the immune response is a memory T cell response.

In a further embodiment the immune response is a CD8+ memory T cell response.

In a further embodiment the immune response is a CD4+ memory T cell response.

20 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a schematic of the construction of plasmid pTH.

Figure 2 is a map of the pSG2 plasmid.

Figure 3 is a schematic of the construction of plasmid pSG2.HBs.

Figure 4 is a map of plasmid pSG2.HBs.

Figures 5A-5B show the nucleotide sequence (SEQ ID NO: 1) of plasmid pSG2.HBs.

Figures 6A-6B show the nucleotide sequence (SEQ ID NO: 2) of the HBV surface antigen (HBsAg) coding region in plasmid pSG2.HBs, and its predicted amino acid sequence (SEQ ID NO: 3).

5 Figure 7 is an agarose gel showing restriction enzyme analysis of plasmid pSG2.HBs.

Figure 8 is a map of the pSC11.HBs plasmid.

Figure 9 is an agarose gel showing restriction enzyme analysis of plasmids pSC11 and pSC11.HBs.

Figure 10 is an agarose gel showing the PCR analysis of recombinant MVA.HBs using  
10 Hbs-specific primers (lanes 1-5) or MVA-specific primers (lanes 6-9).

Figure 11 shows the expected (SEQ ID NO: 4) and actual (SEQ ID NO: 5) nucleotide sequence of the HBsAg gene insert in MVA.HBs, as determined by DNA sequence analysis.

Figure 12 is a graph depicting levels of HBV DNA ("HBV") and levels of alanine  
15 transferase activity ("ALT") in serum samples from subject 102 of Group 1 during the course of treatment. Vertical arrows indicate when doses were administered.

Figure 13 is a graph depicting levels of HBV DNA ("HBV") and levels of alanine transferase activity ("ALT") serum samples from subject 421 of Group A during the course of treatment. Vertical arrows indicate when doses were administered.

20 Figure 14 shows the summed peptide responses after IVS Elispot (Example 8) from patients in Part 2 of the clinical trial study (Example 6) PMBC samples were taken at time points before, during and after therapy with heterologous PrimeBoost immunizations and/or lamivudine. Graphs show mean +/- standard deviation for each patient (A-C) and mean +/- s.e.m for each group (D)

25 A) 4 patients selected at random from Group A. Treated with immunizations with 2mg DNA.HBs at Weeks 0 and 3, immunizations with  $5 \times 10^8$  MVA.HBs at weeks 6 and 9, samples taken at week 0 (before therapy), 10 and 14 (after therapy). All patients show

increased IVS ELISPOT responses after therapy, whereas only two of the four patients exhibited an *ex vivo* ELISPOT response (Table 12)

5 B) 3 patients selected at random from Group B. Treated with 100 mg/day lamivudine administered from week 0 to 14, immunizations with 2 mg DNA.HBs at Weeks 4 and 7, immunizations with  $5 \times 10^8$  MVA.HBs at weeks 10 and 13, samples taken at week -2 (before lamivudine therapy), 4, (before commencing heterologous PrimeBoost immunizations) 14 and 18 (after therapy). Patient 519 showed increased *ex vivo* ELISPOT after PrimeBoost immunotherapy, patient 509 showed a moderate response after lamivudine and after the PrimeBoost immunotherapy, and patient 517 did not  
10 appear to respond to either lamivudine or the PrimeBoost immunotherapy

C) 2 patients selected at random from Group C. Treated with 100 mg/day lamivudine administered from week 0 to 14, samples taken at week -2 (before lamivudine therapy), 4 (during lamivudine therapy) and 18 (after withdrawal of lamivudine). The patients each showed a mild transient response to lamivudine therapy.

15 D): Direct comparison of IVS ELISPOT responses for groups A-C. This is a superimposition of Figures 14A-C showing vaccinations and lamivudine administration.

Mean ELISPOT values of groups  $\pm$  s.e.m are shown. Bar shows the duration of 100 mg/day lamivudine treatment for groups B and C. Arrows show dates of 2 mg DNA.HBs and  $5 \times 10^8$  pfu MVA.HBs vaccinations. Time axis is not to scale and not labeled due to  
20 the different start times used between groups A and B-C (see Figures 14 A-C and Table 7). Intervals between the time points are consistent for the three groups and are shown (6 wks between first two data points, 10 wks between second and third data points, 4 wks between third and fourth data points). NB Group C is missing the third data point and Group A is missing the first data point.

25 The present invention is based, in part, on the discovery that a heterologous prime-boost regimen significantly potentiates immunological and clinical responses to a hepatitis B virus antigen in an individual.

Accordingly, the present invention is directed to a "prime-boost" administration regime, and involves the administration of at least two compositions:

(a) a first composition (priming composition) comprising a source of one or more epitopes of a hepatitis B target antigen; and

(b) a second composition (boosting composition) comprising a source of one or more epitopes of a hepatitis B target antigen, including at least one epitope which is the same as an epitope of the first composition.

The present invention also is based, in part, on the discovery that administration of a priming composition, which comprises a DNA plasmid that is capable of expressing one or more epitopes of a hepatitis B target antigen, significantly potentiates immunological and clinical responses to hepatitis B infection in an individual.

The methods of the present invention can be used to induce a "de novo" immune response against one or more hepatitis B antigens. Alternatively, the methods of the present invention can be used to boost a pre-existing immune response against one or more hepatitis B antigens.

As used herein, "mammal" and "mammalian" refer to any vertebrate animal, including monotreme, marsupials and placental, that suckle their young and either give birth to living young (eutherian or placental mammals) or are egg-laying (metatharian or nonplacental mammals). Examples of mammalian species include humans and primates (e.g., monkeys, chimpanzees), rodents (e.g., rats, mice, guinea pigs), ruminants (e.g., cows, pigs, horses), canines and felines. In a particular embodiment of the invention, the mammal is a human.

The methods described herein can induce, for example, an immune response that is a T cell immune response (e.g., CD8+ T cell, a CD4+ T cell) and/or a humoral (antibody) immune response. In one embodiment, the methods of the present invention induce a humoral (antibody) immune response. In another embodiment, the methods of the present invention induce a T cell immune response. In a particular embodiment, the immune response is a CD8+ T cell immune response. In another embodiment, the immune response is a CD4+ T cell immune response.

T cells fall into two major groups which are distinguishable by their expression of either the CD4 or CD8 co-receptor molecules. CD8-expressing T cells are also known as

cytotoxic T cells by virtue of their capacity to kill infected cells or tumour cells. CD4-expressing T cells, on the other hand, have been implicated in mainly "helping" or "inducing" immune responses.

5 The nature of a T cell immune response can be characterised by virtue of the expression of cell surface markers on the cells. T cells in general can be detected by the presence of TCR, CD3, CD2, CD28, CD5 or CD7 (human only). CD4+ T cells and CD8+ T cells can be distinguished by their co-receptor expression (for example, by using anti-CD4 or anti-CD8 monoclonal antibodies, as is described in the Examples).

10 Since CD4+ T cells recognise antigens when presented by MHC class II molecules, and CD8+ recognise antigens when presented by MHC class I molecules, CD4+ and CD8+ T cells can also be distinguished on the basis of the antigen presenting cells with which they will react.

15 Within a particular target antigen, there may be one or more CD4+ T cell epitopes and one or more CD8+ T cell epitopes. If the particular epitope has already been characterised, this can be used to distinguish between the two subtypes of T cell, for example on the basis of specific stimulation of the T cell subset which recognises the particular epitope.

20 The induction of a T cell response will cause an increase in the number of the relevant T cell type. This may be detected by monitoring the number of cells, or a shift in the overall cell population to reflect an increasing proportion of CD4+ or CD8+ T cells. The number of cells of a particular type may be monitored directly (for example by staining using an anti-CD4+/CD8+ antibody, and then analysing by fluorescence activated cell scanning (FACScan)) or indirectly by monitoring the production of, for example a characteristic cytokine. CD4+ and CD8+ T cell responses are readily distinguished in  
25 ELISPOT assays by specific depletion of one or other T cell subset using appropriate antibodies. CD4+ and CD8+ T cell responses are also readily distinguished by FACS (fluorescence activated cell sorter) analysis.

The methods of the present invention comprise, administering to a mammal, an (one or more) epitope of a (one or more) hepatitis B target antigen. In a particular embodiment,



the epitope is a T cell epitope (*e.g.*, CD8+ T cell epitopes, CD4+ T cell epitopes). A T cell epitope is a short peptide derivable from a protein antigen. Antigen presenting cells can internalise antigen and process it into short fragments which are capable of binding MHC molecules. The specificity of peptide binding to the MHC depends on specific interactions between the peptide and the peptide-binding groove of the particular MHC molecule.

Peptides which bind to MHC class I molecules (and are recognised by CD8+ T cells) are usually between 6 and 12 amino acids, more usually between 8 and 10 amino acids in length. The amino-terminal amine group of the peptide makes contact with an invariant site at one end of the peptide groove, and the carboxylate group at the carboxy terminus binds to an invariant site at the other end of the groove. The peptide lies in an extended conformation along the groove with further contacts between main-chain atoms and conserved amino acid side chains that line the groove. Variations in peptide length are accommodated by a kinking in the peptide backbone, often at proline or glycine residues.

Peptides which bind to MHC class II molecules are usually at least 10 amino acids, more usually at least 13 amino acids in length, and can be much longer. These peptides lie in an extended conformation along the MHC II peptide-binding groove which is open at both ends. The peptide is held in place mainly by main-chain atom contacts with conserved residues that line the peptide-binding groove.

For a given antigen, CD4+ and CD8+ epitopes may be characterised by a number of methods known in the art. When MHC molecules are purified from cells, their bound peptides co-purify with them. The peptides can then be eluted from the MHC molecules by denaturing the complex in acid, releasing the bound peptide, which can be purified (for example by HPLC) and perhaps sequenced.

Peptide binding to many MHC class I and II molecules has been analysed by elution of bound peptides and by X-ray crystallography. From the sequence of a target antigen, it is possible to predict, to a degree, where the Class I and Class II peptides may lie. This is particularly possible for MHC class I peptides, because peptides that bind to a given allelic variant of an MHC class I molecule have the same or very similar amino acid

residues at two or three specific positions along the peptide sequence, known as anchor residues.

Also, it is possible to elucidate CD4+ and CD8+ epitopes using overlapping peptide libraries which span the length of the target antigen. By testing the capacity of such a library to stimulate CD4+ or CD8+ T cells, one can determine the which peptides are  
5 capable of acting as T cell epitopes.

The epitopes either present in, or encoded by the compositions, may be provided in a variety of different forms; such as a recombinant string of one or two or more epitopes, or in the context of the native target antigen, or a combination of both of these. Epitopes  
10 (e.g., CD4+ and CD8+ T cell epitopes) have been identified and can be found in the literature, for many different diseases. It is possible to design epitope strings to generate an immune response against any chosen antigen that contains such epitopes.

Advantageously, the epitopes in a string of multiple epitopes are linked together without intervening sequences so that unnecessary nucleic acid and/or amino acid material is  
15 avoided. In addition to the epitopes from the target antigen, it may be preferable to include one or more other epitopes recognised by T helper cells or B cells, to augment the immune response generated by the epitope string. Particularly suitable T helper cell epitopes are ones which are active in individuals of different HLA types, for example T helper epitopes from tetanus (against which most individuals will already be primed).

20 The source of epitopes in the priming or boosting composition in the method according to the invention can be any suitable vehicle which can be used to deliver and/or express one or more epitopes of the target antigen in a mammal. For example, the source of epitopes in the priming or boosting composition in the method according to the invention can be a non-viral vector or a viral vector (e.g., a replicating viral vector, a non-replicating or  
25 replication-impaired viral vector).

In one embodiment, a heterologous prime-boost regimen is used to minimize cross reactivity between the source of epitopes used for the priming composition and the source of epitopes used for the boosting composition (see U.S. Patent No. 6,663,871B1 and Published U.S. Application No. 2003/0138454, which are incorporated herein by  
30 reference). In this embodiment, the source of epitopes in the priming composition is

different (heterologous) from the source of epitopes in the boosting composition. For example, in one embodiment, the source of epitopes in the priming composition is not a poxvirus vector, particularly when the boosting composition is a poxvirus vector, so that there is minimal cross-reactivity between the priming and boosting compositions. In a particular embodiment, the prime-boost regimen involves administering a priming composition that comprises the DNA plasmid, pSG2.HBs (described herein), followed by a boosting composition that comprises the recombinant virus, MVA.HBs (also described herein).

Alternative suitable viral vectors for use in the priming and boosting compositions according to the invention include a variety of different viruses, disabled so as to be non-replicating or replication-impaired. Such viruses include for example non-replicating adenoviruses such as E1 deletion mutants. Genetic disabling of viruses to produce non-replicating or replication-impaired vectors is well known.

Other suitable viral vectors for use in the priming and boosting compositions are vectors based on herpes virus and Venezuelan equine encephalitis virus (VEE). Suitable bacterial vectors for the priming composition include recombinant BCG and recombinant Salmonella and Salmonella transformed with plasmid DNA (Darji A et al 1997 Cell 91: 765-775).

Alternative suitable non-viral vectors for use in the priming and boosting compositions include lipid-tailed peptides known as lipopeptides, peptides fused to carrier proteins such as KLH either as fusion proteins or by chemical linkage, whole antigens with adjuvant, and other similar systems.

In one embodiment of the invention, the source of epitopes in the priming and/or boosting compositions is a nucleic acid, which may be DNA or RNA, in particular a recombinant DNA plasmid. The DNA or RNA may be packaged, for example in a liposome, or it may be in free form. Nucleic acid molecules, including plasmids and vectors, according to the invention are normally provided in isolated, recombinant and/or purified form.

Accordingly, hepatitis B sequences or other viral sequences are normally provided isolated from their natural environment, and may be free or substantially free of other hepatitis B nucleic acid sequences.

In one embodiment, the source of epitopes in the priming composition is a DNA plasmid (e.g., pSG2.HBs). In a particular embodiment, the source of epitopes in the priming composition is a nucleic acid molecule, preferably a DNA plasmid, comprising the nucleotide sequence of SEQ. ID NO: 1. In another embodiment, the source of epitopes in the priming composition is a nucleic acid molecule, preferably a DNA plasmid, comprising a nucleotide sequence that is at least 90%, 95%, 98% or 99% homologous or identical to SEQ ID NO:1.

In other embodiments the source of epitopes in the priming and/or boosting compositions comprise a nucleotide sequence that encodes the amino acid sequence of SEQ. ID NO. 3 or a fragment thereof. In another embodiment, the source of epitopes in the priming and/or boosting compositions comprise a nucleotide sequence that encodes an amino acid sequence that is at least 90%, 95%, 98% or 99% identical to the amino acid sequence of SEQ. ID NO. 3 or a fragment thereof. In a further embodiment, the source of epitopes in the priming and/or boosting compositions comprise a nucleotide sequence that encodes an amino acid sequence with up to 1, 3, 5, 10, or 20 amino acid additions, deletions or substitutions relative to the amino acid sequence of SEQ. ID NO: 3. For example, the source of epitopes may be a non-replicating or replication-impaired poxvirus vector such as a modified vaccinia virus Ankara (MVA), comprising a nucleotide sequence encoding SEQ ID NO: 3 or encoding an amino acid sequence at least 90, 95, 98 or 99% identical to SEQ ID NO: 3. Poxvirus vectors are especially preferred in boosting compositions of the invention, and are discussed in detail elsewhere herein.

In another embodiment of the invention, the source of epitopes in the priming and/or boosting compositions is a peptide, polypeptide, protein, polyprotein or particle comprising two or more epitopes, present in a recombinant string of epitopes or in a target antigen. Polyproteins include two or more proteins which may be the same, or different, linked together. The epitopes in or encoded by the priming or boosting composition are provided in a sequence which does not occur naturally as the expressed product of a gene in the parental organism from which the target antigen may be derived.

In another embodiment, the source of the epitopes in the boosting composition is a non-replicating or replication impaired recombinant poxvirus vector. In a particular embodiment, the source of epitopes in the boosting composition is a vaccinia virus vector

such as MVA, NYVAC or a strain derived therefrom. Alternatives to vaccinia vectors include avipox vectors such as fowl pox or canarypox vectors. Particularly suitable as an avipox vector is a strain of canarypox known as ALVAC (commercially available as Kanapox), and strains derived therefrom. In a particular embodiment, the source of the epitopes in the boosting composition is a non-replicating or replication-impaired poxvirus vector, normally a modified vaccinia virus Ankara (MVA), that comprises the nucleotide sequence of SEQ. ID NO: 4 or SEQ. ID NO: 5 (e.g., MVA.HBs). In another embodiment, the source of the epitopes in the boosting composition is a non-replicating or replication-impaired poxvirus vector, normally a modified vaccinia virus Ankara (MVA), that comprises a nucleotide sequence that is at least 90%, 95%, 98% or 99% homologous or identical to SEQ. ID NO: 4 or SEQ. ID NO: 5.

The term "non-replicating" or "replication-impaired" as used herein means not capable of replication to any significant extent in the majority of normal mammalian cells or normal human cells. Viruses which are non-replicating or replication-impaired may have become so naturally (i.e. they may be isolated as such from nature) or artificially e.g. by breeding *in vitro* or by genetic manipulation, for example deletion of a gene which is critical for replication. There will generally be one or a few cell types in which the viruses can be grown, such as CEF cells for MVA.

Replication of a virus is generally measured in two ways: 1) DNA synthesis and 2) viral titre. More precisely, the term "nonreplicating or replication-impaired" as used herein and as it applies to poxviruses means viruses which satisfy either or both of the following criteria:

- 1) exhibit a 1 log (10 fold) reduction in DNA synthesis compared to the Copenhagen strain of vaccinia virus in MRC-5 cells (a human cell line);
- 2) exhibit a 2 log reduction in viral titre in HELA cells (a human cell line) compared to the Copenhagen strain of vaccinia virus.

Examples of poxviruses which fall within this definition are MVA, NYVAC and avipox viruses, while a virus which falls outside the definition is the attenuated vaccinia strain M7.

Modified vaccinia virus Ankara (MVA) is a strain of vaccinia virus which does not replicate in most cell types, including normal human tissues. MVA was derived by serial passage > 500 times in chick embryo fibroblasts (CEF) of material derived from a pox lesion on a horse in Ankara, Turkey (Mayr et al. *Infection* (1975) 33: 6-14.). It was shown to be replication-impaired yet able to induce protective immunity against veterinary poxvirus infections. MVA was used as a human vaccine in the final stages of the smallpox eradication campaign, being administered by intracutaneous, subcutaneous and intramuscular routes to > 120,000 subjects in southern Germany. No significant side effects were recorded, despite the deliberate targeting of vaccination to high risk groups such as those with eczema (Mayr et al. *Bakteriol B.* (1978) 167: 375- 90).

The safety of MVA reflects the avirulence of the virus in animal models, including irradiated mice and following intracranial administration to neonatal mice. The non-replication of MVA has been correlated with the production of proliferative white plaques on chick chorioallantoic membrane, abortive infection of non-avian cells, and the presence of six genomic deletions totalling approximately 30 kb. The avirulence of MVA has been ascribed partially to deletions affecting host range genes K1 L and C7L, although limited viral replication still occurs on human TK-143 cells and African Green Monkey CV-1 cells. Restoration of the K1 L gene only partially restores MVA host range. The host range restriction appears to occur during viral particle maturation, with only immature virions being observed in human HeLa cells on electron microscopy (Sutter et al. 1992). The late block in viral replication does not prevent efficient expression of recombinant genes in MVA.

Poxviruses have evolved strategies for evasion of the host immune response that include the production of secreted proteins that function as soluble receptors for tumour necrosis factor, IL-1 p, interferon (IFN)- $\alpha$  and IFN- $\gamma$ , which normally have sequence similarity to the extracellular domain of cellular cytokine receptors (such as chemokine receptors).

These viral receptors generally inhibit or subvert an appropriate host immune response, and their presence is associated with increased pathogenicity. The IL-1 p receptor is an exception: its presence diminishes the host febrile response and enhances host survival in the face of infection. MVA lacks functional cytokine receptors for interferon  $\gamma$ , interferon  $\alpha$ , Tumour Necrosis Factor and CC chemokines, but it does possess the potentially

beneficial IL-1 receptor. MVA is the only known strain of vaccinia to possess this cytokine receptor profile, which theoretically renders it safer and more immunogenic than other poxviruses. Another replication impaired and safe strain of vaccinia known as NYVAC is fully described in Tartaglia et al. (Virology 1992, 188: 217-232).

- 5 Poxvirus genomes can carry a large amount of heterologous genetic information. Other requirements for viral vectors for use in vaccines include good immunogenicity and safety. In one embodiment the poxvirus vector may be a fowlpox vector, or derivative thereof.

10 It will be evident that vaccinia virus strains derived from MVA, or independently developed strains having the features of MVA which make MVA particularly suitable for use in a vaccine, will also be suitable for use as an immunotherapeutic in the invention. In particular, MVA containing an inserted string of epitopes, or polyepitope gene, has been previously described in WO 98/56919.

15 The methods of the present invention can comprise administering one or more (a plurality) doses of the priming composition, followed by one or more doses of the first boosting composition to induce an immune response. In a particular embodiment, both the priming composition and boosting composition are administered in multiple doses.

20 The methods of the present invention also can comprise administering one or more (a plurality) doses of the priming composition to induce an immune response. In one embodiment, the priming composition is administered in multiple doses. In a particular embodiment, the priming compositions is administered twice.

25 The timing of the individual doses will depend on the individual. For example, the timing of the priming and boosting doses can be in the region of from about one week to three weeks, about 6 weeks to 9 weeks, about 9 weeks to 12 weeks, about 12 weeks to 15 weeks, about 15 to about 18 weeks and about 18 weeks to about 21 weeks apart. In particular embodiments, the timing of the priming and boosting doses can be about 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 week, 11 weeks, 12, weeks, 13 weeks, 14, weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks or 25 weeks apart.

The target antigen for use in the methods of the present invention can be any antigen that is characteristic of the target disease (e.g., hepatitis B). In one embodiment, the target antigen is derived from the hepatitis B virus (HBV). Suitable antigens from the hepatitis B virus include, but are not limited to, surface (e.g., HBsAg) and/or core (e.g., HBcAg or HBeAg - soluble form) polymerase or x-protein, as well as any protein fragment thereof.

The target antigen may be an antigen which is recognised by the immune system after infection with the disease. Alternatively the antigen may be normally "invisible" to the immune system such that the method induces a non-physiological T cell response. This may be helpful in diseases where the immune response triggered by the disease is not effective (for example does not succeed in clearing the infection), as it may open up another line of attack.

The compositions described herein may be employed as therapeutic or prophylactic compositions (e.g., therapeutic compositions, immunotherapeutics, vaccines). Whether prophylactic or therapeutic immunisation is more appropriate will usually depend upon the nature of the disease.

The compositions of the present invention can exhibit a therapeutic effect when administered to a mammal, particularly a human. A therapeutic effect can be, among others, a decrease in HBV viral load or HBeAg in a subject's serum, an increase in IFN-gamma-secreting peptide specific T cells, elevation of the level of one or more liver enzymes, such as alanine transferase (ALT) and aspartate transferase (AST), and/or seroconversion of one or more HBV antigens. As used herein, seroconversion refers to the loss of one or more viral antigens from the serum of a subject, followed by the appearance of antibodies against the one or more viral antigens in the serum of the subject.

The methods of the present invention have been demonstrated using hepatitis B virus (HBV) antigens. In one embodiment, the method can be used to induce an immune response against multiple epitopes of HBV in a human. In a particular embodiment, the immune response is induced by an epitope of the HBV surface antigen (HBsAg). In a further embodiment, the immune response is induced against either the small form of the HBV surface antigen (small S antigen), the medium form of the HBV surface antigen



(medium S antigen), or a combination thereof. In another embodiment, the immune response is induced by an epitope of the HBV surface antigen (HBsAg), in combination with other HBV-derived antigens, such as the core polymerase or x-protein.

Induction of an immune response against hepatitis B infection can be assessed using any technique that is known by those of skill in the art for determining whether an immune response has occurred. Suitable methods of detecting an immune response for the present invention include, among others, detecting a decrease in HBV viral load or HBeAg in a subject's serum, detection of IFN-gamma-secreting peptide specific T cells, and detection of elevated levels of one or more liver enzymes, such as alanine transferase (ALT) and aspartate transferase (AST). In one embodiment, the detection of IFN-gamma-secreting peptide specific T cells is accomplished using an ELISPOT assay.

In a particular embodiment, the induction of an immune response against hepatitis B is evidenced by seroconversion. In a further embodiment of the invention, seroconversion is detected during a period of less than 14 days after administration of the priming composition.

There is a clear need for the development of improved therapies for the treatment of hepatitis B. In order to test a prime-boost strategy for inducing anti-HBV CTL responses, recombinant DNA and vaccinia virus constructions are required.

To produce a DNA vector suitable for use in humans, plasmid pSG2 was constructed and validated by sequencing. This contains an enhancer/promoter/intron cassette for efficient expression of inserted antigens in mammalian cells, a polylinker cloning site, the bovine growth hormone transcription termination sequence, and sequences for propagation and selection in *E. coli*. The use of a kanamycin resistance marker avoids the risk of residual ampicillin-based contaminants in the manufactured product causing problems in sensitive individuals.

Plasmid pSG2.HBs was constructed by insertion of a 1,082 base pair (bp) fragment containing the *pre-S2* and *S* genes of HBV into the polylinker cloning site of plasmid pSG2. Plasmid pSG2.HBs contains the CMV IE promoter with intron A, for driving expression of the HBV small S and medium S antigens in mammalian cells, followed by

the bovine growth hormone transcription termination sequence. The plasmid also contains the kanamycin resistance gene and is capable of replication in *E. coli* but not in mammalian cells. The sequence of the poly-epitope gene was confirmed by sequencing, and both pSG2 and pSG2.HBs plasmids were characterised by restriction enzyme analysis. The complete sequence of plasmid pSG2.HBs was determined.

Plasmid pSG2.HBs contains genes encoding the small S and medium S antigen HBV epitopes under the control of an efficient promoter for expression in mammalian cells. The plasmid also carries sequences for propagation and selection in *E. coli* but is unable to replicate in mammalian cells. As shown herein, pSG2.HBs is a suitable DNA immunisation vector for use in humans.

Modified vaccinia virus Ankara (MVA) was selected as the vaccinia strain for development of a recombinant virus containing HBV epitopes. Recombinant MVA is considered to be a promising human vaccine candidate because of its safety profile and immunogenic properties.

Plasmid pSC11 (Chakrabarti *et al* 1985) contains the vaccinia late/early P7.5 promoter (Cochran *et al* 1985) to drive expression of the inserted antigen, and the vaccinia late promoter P11 driving expression of the *lacZ* marker gene. It also contains the left and right fragments of the vaccinia thymidine kinase (*TK*) gene flanking the region containing the *lacZ* gene and the inserted antigen so that these sequences can be inserted into the MVA genome by homologous recombination at the *TK* locus, thereby inactivating the *TK* gene.

Plasmid pSC11.HBs was constructed by insertion of a *HindIII-NsiI* fragment containing the *pre-S2* and *S* genes of HBV into the polylinker region of plasmid pSC11 (Figure 8). Plasmid pSC11.HBs therefore contains the vaccinia late/early P7.5 promoter driving expression of the inserted S antigen, and the vaccinia late promoter P11 driving expression of the *lacZ* marker gene, flanked by the left and right fragments of the vaccinia thymidine kinase (*TK*) gene.

The DNA fragments generated following digestion of pSC11 and pSC11.HBs with restriction enzymes *BamHI* and *XhoI* is shown in Figure 9.

Plasmid pCMVS2.S contains the *pre-S2* and *S* sequences of HBV strain *ayw*. The plasmid contains a *HinDIII* site immediately 5' to the *pre-S2* gene and an *NsiI* site 3' to the *S* gene. This fragment was isolated and treated with Klenow polymerase. This treatment filled in the overhang generated by cutting with *HinDIII* and removed the overhang  
5 generated by cutting with *NsiI*. The resulting 1,085 base pair (bp) blunt-ended fragment was inserted into the *SmaI* site of plasmid pSC11 to generate plasmid pSC11.HBs.

A novel immunotherapy comprising the DNA plasmid, pSG2.HBs, and the MVA viral vector, MVA.HBs, containing a source of epitopes from the HBV surface antigen, has been demonstrated. The data provided herein was designed to evaluate the safety and  
10 immunogenicity of different doses and dosing regimens of a heterologous "PrimeBoost" immunisation schedule comprising pSG2.HBs "priming" followed by MVA.HBs "boosting" in subjects with chronic HBV infection.

This study evaluates the safety, immunogenicity and clinical response of increasing doses of DNA plasmid (pSG2.HBs) and MVA viral vector (MVA.HBs) containing a source of  
15 epitopes from the HBV surface antigen. The data indicate that pSG2.HBs and MVA.HBs are able to stimulate immunologically non-responsive patients as well as increase pre-existing immune responses.

The present invention is also directed to plasmids and recombinant viral vectors used in the methods described herein. In one embodiment, the invention is directed to an isolated  
20 plasmid comprising the nucleotide sequence of SEQ ID NO: 1. In another embodiment, the present invention is directed to an isolated recombinant replication-deficient poxvirus (e.g., MVA) comprising the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

The priming and boosting compositions used in the method of the invention may conveniently be provided in the form of a "combined preparation" or kit. The priming  
25 and boosting compositions may be packaged together or individually for separate sale. The priming and boosting compositions may be used simultaneously, separately or sequentially for inducing an immune response against a target antigen.

The kit may comprise other components for mixing with one or both of the compositions before administration (such as diluents, carriers, adjuvants etc.- see below).

The kit may also comprise written instructions concerning the vaccination protocol, for example to administer the priming composition one or more times followed by the boosting composition one or more times.

5 In one embodiment, the kit comprises multiple (e.g. two) doses of the priming composition and/or multiple (e.g. two) doses of the boosting composition, and instructions to administer the priming composition one or more times (e.g. twice) followed by the boosting composition one or more times (e.g. twice).

10 The present invention also relates to a product comprising the priming and boosting compositions as defined above. The product may be in the form of a pharmaceutical composition. A pharmaceutical composition may comprise a nucleic acid molecule or a virus according to the invention.

15 The pharmaceutical composition may also comprise, for example, a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice.

In particular, a composition comprising a DNA plasmid vector may comprise granulocyte macrophage-colony stimulating factor (GM-CSF), or a plasmid encoding it, to act as an adjuvant; beneficial effects are seen using GM-CSF in polypeptide form. Adjuvants such as QS21 or SBAS2 (Stoute J A et al. 1997 N Engl J Medicine 226: 86-91) may be used  
20 with proteins, peptides or nucleic acids to enhance the induction of T cell responses.

In the pharmaceutical compositions of the present invention, the composition may also be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), or solubilising agent(s).

25 The pharmaceutical composition could be for veterinary (i.e. animal) usage or for human usage.

Nucleic acid molecules and viruses according to the invention may be used for treatment of the human or animal body by therapy, and especially for treating hepatitis B. Treatment includes preventative treatment such as vaccination.

In one aspect, the invention is use of a nucleic acid molecule or poxvirus of the invention in the manufacture of a medicament for treating hepatitis B. The medicament may be for inducing a *de novo* immune response, or for boosting a pre-existing immune response against hepatitis B in an individual. The medicament may be for administration according to a regime described herein, for example it may be for administration in multiple doses, e.g. two doses. Medicaments comprising poxvirus are normally used as boosting compositions for administration following administration of a nucleic acid priming composition to an individual. Thus, in other aspects, the invention provides a priming composition and a boosting composition for sequential administration to an individual to treat hepatitis B, and use of a priming composition and a boosting composition in the manufacture of a medicament for sequential administration to an individual to treat hepatitis B. Suitable priming and boosting compositions are described in detail elsewhere herein.

In general, a therapeutically effective dose or amount of the compositions of the present invention is administered. The dosage for DNA compositions (e.g., DNA priming composition; DNA boosting composition) can be from about 0.5 mg to about 10 mg. In particular embodiments, the dosage for DNA compositions is from about 1 mg to about 4 mg. In a particular embodiment, the dosage for DNA compositions is about 2 mg. The dosage for vector (e.g., viral vector such as MVA) compositions (e.g., vector priming composition; vector boosting composition) can be from about  $1 \times 10^7$  pfu to about  $1 \times 10^{10}$  pfu. In particular embodiments, the dosage for vector compositions is from about  $2 \times 10^7$  to about  $5 \times 10^9$  pfu. In a particular embodiment, the dosage of the vector composition is from about  $5 \times 10^7$  pfu to about  $1 \times 10^9$ .

The priming and boosting compositions of the present invention can be administered using any suitable route of administration. Tablets or capsules of the agents may be administered singly or two or more at a time, as appropriate. It is also possible to administer the compositions of the present invention in sustained release formulations.

Typically, the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be

individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Where appropriate, the pharmaceutical compositions can be administered by inhalation, by use of a gene gun, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

For some applications, preferably the compositions are administered orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents.

For parenteral administration, the compositions are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.

For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

The physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. It is to be noted that whilst the above-mentioned dosages are exemplary of the

average case there can, of course, be individual instances where higher or lower dosage ranges are merited and such dose ranges are within the scope of this invention.

In some applications, generally, in humans, oral administration of the agents of the present invention is the preferred route, being the most convenient and can in some cases avoid disadvantages associated with other routes of administration - such as those associated with intracavernosal (i.c.) administration. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may be administered parenterally, e.g. sublingually or buccally.

For veterinary use, the composition of the present invention is typically administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular animal. However, as with human treatment, it may be possible to administer the composition alone for veterinary treatments.

**Example 1 Construction and characterisation of a recombinant DNA plasmid expressing HBV antigens**

In order to test a prime-boost strategy for inducing an anti-HBV T-cell immune response, recombinant DNA and vaccinia virus constructs have been made containing a gene encoding the HBV surface antigen. The HBsAg gene of HBV has three potential initiation codons that divide the gene into pre-S1, pre-S2 and S regions. The small S antigen is encoded by the S region and is 226 amino acids in length. The medium S antigen is encoded by the S and pre-S2 regions and is 281 amino acids in length. This report describes the construction of a recombinant plasmid expressing the S and pre-S2 regions of HBV.

A DNA plasmid containing the S and pre-S2 regions of the HBsAg gene of HBV was constructed and characterized.

## MATERIALS AND METHODS

### Materials and reagents

#### Buffers and reagents

#### Buffers and solutions:

- 5        Chemical reagents and buffers were purchased from Sigma.

#### Enzymes and molecular biology reagents:

Klenow polymerase (NEB)

T4 ligase (Promega M1801)

Restriction endonucleases (NEB)

- 10    DNA chromatography columns (Qiagen GmbH)

Agarose (Sigma A9539)

#### Culture reagents:

DH5 $\alpha$  competent cells (Gibco 18258-012)

Bacterial growth media LB (Sigma L7275)

- 15    Ampicillin (Sigma A2804)

Kanamycin (Sigma K0879)

#### DNA reagents:

Oligonucleotides were purchased from R&D Systems Europe Ltd, 4-10 The Quadrant, Barton Lane, Abingdon, Oxon OX14 3YS.

- 20        Plasmid pRc/CMV was purchased from Invitrogen, PO Box 2312, 9704 CH Groningen, The Netherlands.

Plasmid pCMVS2.S was a gift from Dr H Davies (Loeb Medical Research Institute, Ottawa Civic Hospital, ON, Canada).



Plasmids pUC4K and pUC19 were purchased from Pharmacia, 100 Route, 206 North Peapack, New Jersey 07977, USA.

Plasmid pBB14 contains the expression efficient enhancer/promoter/intron A cassette of the human cytomegalovirus (hCMV) strain AD169 (Whittle *et al* 1987).

- 5 Plasmid pSC11 was a gift from Dr E Cerundolo, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS.

#### Cells and culture medium:

- The bacterial host strain used for DNA manipulation and propagation was *Escherichia coli* strain DH5 $\alpha$ . Cells transformed with plasmid DNA containing the
- 10  $\beta$ -lactamase gene were propagated in LB liquid medium containing 50  $\mu$ g/mL ampicillin or on plates containing the same medium plus 2% (w/v) agar. Cells transformed with plasmid DNA containing the kanamycin resistance marker were propagated in LB liquid medium containing 25  $\mu$ g/mL kanamycin or on plates containing the same medium plus 2% (w/v) agar.

#### 15 Experimental Methods

Unless stated otherwise, all DNA manipulations were carried out using standard molecular biology techniques as described in Current Protocols in Molecular Biology, Ed. FM Ausubel, John Wiley & Sons or according to the manufacturers' instructions.

#### 20 Construction of plasmid pSG2

- Plasmid pSG2 was derived from plasmid pTH. To construct plasmid pTH, plasmid pRc/CMV was digested with *Bam*HI and the fragments carrying the ColB1 origin of replication,  $\beta$ -lactamase (for ampicillin resistance), the hCMV promoter and the bovine growth hormone polyadenylation site were gel-purified. These fragments
- 25 were re-ligated to create plasmid pCMVBam. This plasmid was then partially cut with *Bam*HI, the single-cut DNA was gel-purified, the staggered ends filled in with

Klenow polymerase and re-ligated. The resulting plasmid, containing a single *Bam*HI site in the polylinker region was designated pCMV. The enhancer/promoter region of pCMV was then excised using *Mlu*I and *Hin*DIII restriction endonucleases and a fragment from plasmid pEE14 containing the enhancer/intermediate early promoter/intron A region of hCMV was ligated between the sites to create plasmid pTH.

To construct plasmid pSG2, the ampicillin resistance (Amp-r) marker in pTH was replaced with the kanamycin resistance marker (Kan-r) from the bacterial transposon Tn903 present in plasmid pUC4K. The Kan-r gene was excised from pUC4K on a *Bsp*HI fragment and ligated with pTH, also cut with *Bsp*HI which released the Amp-r gene. Subsequently, the plasmid underwent a spontaneous deletion of the sequence following the Kan-r gene. This deletion was found to be stable and did not affect function of the plasmid.

#### Construction of plasmid pSG2.HBs

The source of the HBV sequence in plasmid pSG2.HBs was plasmid pCMVS2.S which contains the *pre-S2* and *S* sequences of HBV strain ayw. The plasmid contains a *Hin*DIII site immediately 5' to the *pre-S2* gene and an *Bam*HI site 3' to the *S* gene.

Insertion of the HBsAg sequence into pSG2 was carried out via the following steps. Firstly, pCMVS2.S was cut with *Hin*DIII and *Bam*HI to generate a fragment containing the 5' end of the sequence. The 3' end of the HBsAg sequence was isolated from pSC11.HBs as a *Bam*HI-*Eco*RI fragment. These fragments were inserted into the polylinker region of plasmid pUC19. The resulting plasmid was partially digested with *Hin*DIII and *Eco*RI and the HBsAg fragment was isolated and inserted into plasmid pSG2, also partially cut with *Hin*DIII and *Eco*RI. The overall insert size of the fragment inserted in pSG2.HBs is 1,082 bp (plus the 5' *Hin*DIII and 3' *Eco*RI sites).

#### Purification of plasmid DNA

DNA plasmids were propagated in *E. coli* strain DH5 $\alpha$ , purified using anion exchange chromatography columns (Qiagen) and resuspended in water. The concentration was calculated by spectrophotometric analysis at 260 nm and the DNA was then diluted in PBS.

#### Sequencing of plasmid pSG2.HBs

The complete nucleotide sequence of plasmid pSG2.HBs was determined by Qiagen GmbH (Max-Volmer Str 4, 40724 Hilden, Germany).

#### Restriction enzyme analysis of plasmid pSG2.HBs

Plasmid pSG2.HBs was digested with *Bam*HI and *Xho*I restriction enzymes (separate digests) and the resulting fragments were separated on an agarose gel at 100V for 30 minutes. Size markers used were  $\phi$ X174 DNA digested with *Hae*III and  $\lambda$  DNA digested with *Hin*DIII. The expected size pattern of fragments (base pairs) generated by these digestions are:

| Restriction enzymes | pSG2.HBs                 |
|---------------------|--------------------------|
| <i>Bam</i> HI       | 5413                     |
| <i>Xho</i> I        | 2927, 1164, 973, 324, 25 |

## RESULTS

#### Construction of plasmid pSG2

The construction of plasmid pTH is shown in Figure 1. Plasmid pSG2 was derived from pTH by replacing the ampicillin resistance maker in pTH with a kanamycin resistance marker. A map of plasmid pSG2 is shown in Figure 2.

#### Construction of plasmid pSG2.HBs

Plasmid pSG2.HBs was constructed by insertion of a 1,082 bp fragment containing the *pre-S2* and *S* genes of HBV into the polylinker cloning site of plasmid pSG2. A summary of the cloning steps involved is shown in Figure 3. Plasmid

- 5 pSG2.HBs contains the CMV IE promoter with intron A for driving expression of the HBV *pre-S2/S* antigen in mammalian cells, followed by the bovine growth hormone transcription termination sequence. The plasmid also contains the kanamycin resistance gene and is capable of replication in *E.coli* but not in mammalian cells. A map of plasmid pSG2.HBs is shown in Figure 4.

#### 10 Characterisation of plasmid pSG2.HBs

##### Complete sequence of plasmid pSG2.HBs

The complete sequence of plasmid pSG2.HBs is shown in Figures 5A-5B.

##### Sequence of the HBV S antigen gene in plasmid pSG2.HBs

- The sequence of the 1,082 bp DNA insert in plasmid pSG2.HBs is shown in  
15 Figures 6A-6B. The insert contains an 843 bp open reading frame (encoding the *pre-S2* and *S* regions of the HBsAg gene) followed by a translation stop codon and a 3' untranslated region.

##### Restriction enzyme analysis of plasmid pSG2.HBs

- The DNA fragments generated following digestion of plasmid pSG2.HBs with  
20 restriction enzymes *Bam*HI and *Xho*I is shown in Figure 7.

#### DISCUSSION

- Plasmid pSG2.HBs was generated by insertion of a gene fragment containing the *pre-S2* and *S* sequences of HBV strain *ayw* into the polylinker cloning region of pSG2. The complete sequence of plasmid pSG2.HBs was determined and the plasmid is  
25 5,413 bp in size.

Plasmid pSG2.HBs was also characterised by restriction enzyme analysis. The pattern of fragments generated, and their sizes, were consistent with the predicted pattern based on the sequence of the plasmid.

- 5 Plasmid pSG2.HBs contains the *pre-S2* and *S* regions of the HBsAg gene of HBV strain *ayw* under control of an efficient promoter for expression in mammalian cells. The plasmid also carries sequences for propagation and selection in *E. coli* but is unable to replicate in mammalian cells. It is, therefore, a suitable DNA immunisation vector for use in humans.

10 **Example 2 Construction and characterisation of recombinant MVA expressing HBV antigens**

- A variety of attenuated recombinant viral vectors have been developed as antigen delivery systems. However, not all attenuated viruses are replication-incompetent in mammalian hosts and the use of attenuated but replication-competent  
15 viruses can lead to side effects, particularly in immunocompromised individuals.

- Modified vaccinia virus Ankara (MVA) is a strain of vaccinia virus that does not replicate in most cell types, including normal human tissues (Mayr *et al* 1978). MVA was derived by multiple passages of a vaccinia virus from a horse pox lesion and was administered to 120,000 people in the last stages of the smallpox eradication  
20 program in Germany. The genome of MVA has been fully sequenced and the virus has six genomic deletions totalling 30kb. The avirulence of MVA has been ascribed in part to deletions of host range genes and it also lacks several genes coding for immunomodulatory proteins. Since infection with replication-impaired viruses is abortive and therefore delivers a lower dose of antigen *in vivo*, it has been speculated  
25 that these viruses would be less immunogenic than their replication-competent parental strains. However, in studies comparing replication-impaired vaccinia viruses with a replication-competent virus, only boosting DNA-primed animals with replication-impaired poxviruses induced high levels of protection against malaria (Schneider *et al* 1998). Recombinant MVA is therefore considered to be a promising

human vaccine candidate because of its safety profile and immunogenic properties.

- In order to test a prime-boost strategy for inducing anti-HBV CTL responses, recombinant DNA and vaccinia virus constructions have been made containing a gene encoding the HBV surface antigen (HBsAg). The HBsAg gene of HBV has three potential initiation codons that divide the gene into pre-S1, pre-S2 and S regions. The small S antigen is encoded by the S region and is 226 amino acids in length. The medium S antigen is encoded by the S and pre-S2 regions and is 281 amino acids in length. This report describes the construction of a recombinant MVA expressing the S and pre-S2 regions of HBV.
- 10 A recombinant MVA containing the S and pre-S2 regions of the HBsAg gene of HBV was constructed and characterized.

## MATERIALS AND METHODS

### Materials and reagents

#### Buffers and reagents

15 Buffers and chemicals:

Chemical reagents and buffers were purchased from Sigma

#### Enzymes and molecular biology reagents:

T4 ligase (Promega M1801)

Restriction endonucleases (NEB)

20 DNA chromatography columns and buffers (Qiagen GmbH)

Agarose (Sigma A9539)

Ethidium bromide (Sigma E-151)

2 x Reddy master mix 2.5mM MgCl<sub>2</sub> (AB Gene AB-0619/LD/DC)

#### Bacterial culture reagents:

25 Bacterial growth medium LB (Sigma L7275)

Ampicillin (Sigma A2804)

Kanamycin (Sigma K0879)

DH5 $\alpha$  competent cells (Gibco 18258-012)

Tissue culture reagents:

5 Fetal calf serum (FCS) (Sigma)

Superfect (Qiagen)

MEM (Sigma)

Penicillin (100 units) (Sigma)

Streptomycin (100  $\mu$ g/mL) (Sigma)

10 Tissue culture plates (Falcon)

X-gal (Promega)

Formaldehyde (37%) (Sigma)

Carboxymethyl cellulose (CMC) (BDH 276494N)

CMC overlay: Prepare 3% CMC in water and autoclave. Mix 1:1 with 2 x MEM

15 containing 4% FCS and 2 x penicillin/streptomycin.

Immunoassay reagents:

96-well nitrocellulose plates (Milliscreen MAHA, Millipore, UK)

24-well plates (Corning Costar)

Bovine serum albumin (BSA) (Sigma)

20 Fast DAB kit (Sigma D-0426)

Anti-mouse IgG peroxidase conjugate (Sigma Immunochemicals A-2554)

Anti-MVA antibody Mouse serum from BALB/c mice immunised twice with  $1 \times 10^6$   
plaque-forming units (pfu) of MVA

DNA and viral reagents

25 Oligonucleotides were purchased from R&D Systems Europe Ltd, 4-10 The  
Quadrant, Barton Lane, Abingdon, Oxon OX14 3YS or from MWG Biotech AG,

Anzinger Strasse 7, D-85560 Ebersberg, Germany.

Plasmid pCMVS2.S was a gift from Dr H Davies (Loeb Medical Research Institute, Ottawa Civic Hospital, ON, Canada).

Plasmid pSC11 was a gift from Dr E Cerundolo, Institute of Molecular  
5 Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS.

Non-recombinant MVA was obtained from Anton Mayr, University of Munich Germany.

#### Cells and culture medium

The bacterial host strain used for DNA manipulation and propagation was  
10 *Escherichia coli* strain DH5 $\alpha$ . Cells transformed with plasmid DNA containing the  $\beta$ -lactamase gene were propagated in LB liquid medium containing 50  $\mu$ g/mL ampicillin or on plates containing the same medium plus 2% (w/v) agar. Cells transformed with plasmid DNA containing the kanamycin resistance marker were propagated in LB liquid medium containing 25  $\mu$ g/mL kanamycin or on plates  
15 containing the same medium plus 2% (w/v) agar.

Recombinant and non-recombinant vaccinia viruses were routinely propagated in primary chicken embryo fibroblasts (CEFs) grown in minimal essential medium (MEM) supplemented with 10% (v/v) foetal calf serum (FCS). For growth, CEFs were cultivated in MEM with 10% (v/v) FCS and incubated at 37°C. For  
20 maintenance, CEFs were incubated in MEM with 2% (v/v) FCS and incubated at 30°C. MVA is unable to infect cells at a FCS concentration of 10% (v/v). For infection, CEFs are therefore grown in MEM with 10% (v/v) FCS, rinsed in phosphate-buffered saline (PBS) and virus added in MEM containing 2% (v/v) FCS.

#### Experimental Methods

25 Unless stated otherwise, all DNA manipulations were carried out using standard molecular biology techniques as described in Current Protocols in Molecular



Biology, Ed. F. M. Ausubel, John Wiley & Sons or according to the manufacturers' instructions.

#### Construction of plasmid pSC11.HBs

Plasmid pSC11 (Chakrabarti *et al* 1985) contains the vaccinia late/early P7.5 promoter (Cochran *et al* 1985) to drive expression of the inserted antigen, and the vaccinia late promoter P11 driving expression of the *lacZ* marker gene. It also contains the left and right fragments of the vaccinia thymidine kinase (*TK*) gene flanking the region containing the *lacZ* gene and the inserted antigen so that these sequences can be inserted into the MVA genome by homologous recombination at the *TK* locus, thereby inactivating the *TK* gene.

Plasmid pCMVS2.S contains the *pre-S2* and *S* sequences of HBV strain *ayw*. The plasmid contains a *HinDIII* site immediately 5' to the *pre-S2* gene and an *NsiI* site 3' to the *S* gene. This fragment was isolated and treated with Klenow polymerase. This treatment filled in the overhang generated by cutting with *HinDIII* and removed the overhang generated by cutting with *NsiI*. The resulting 1,085 base pair (bp) blunt-ended fragment was inserted into the *SmaI* site of plasmid pSC11 to generate plasmid pSC11.HBs (Figure 8).

#### Purification of plasmid DNA

DNA plasmids were propagated in *E. coli* strain DH5 $\alpha$ , purified using anion exchange chromatography columns (Qiagen) and resuspended in water. The concentration was calculated by spectrophotometric analysis at 260 nm and the DNA was then diluted in PBS.

#### Restriction enzyme analysis of plasmids pSC11 and pSC11.HBs

Plasmids pSC11 and pSC11.HBs were digested with *BamHI* and *XhoI* (separate digests) and the resulting fragments were separated on an agarose gel at 100V for 40

minutes. Size markers used were  $\phi$ X174 DNA/*Hae*III and  $\lambda$  DNA/*Hin*DIII. The expected size pattern of fragments (base pairs) generated by these digestions were:

| Restriction enzymes | pSC11           | pSC11.HBs            |
|---------------------|-----------------|----------------------|
| <i>Bam</i> HI       | 4426, 3071, 386 | 4996, 3071, 515, 386 |
| <i>Xho</i> I        | 7883            | 8434, 534            |

#### Selection of MVA.HBs

Recombinant viruses were produced by infecting primary CEFs with MVA, then transfecting the same cells with the appropriate shuttle vector. CEF cultures (90% confluent) were infected with 1-2 pfu/cell wild type MVA in 1 mL MEM with 2% (v/v) FCS for 120 minutes in a standard tissue culture incubator (37°C, 5% CO<sub>2</sub>). After infection, the cells were transfected with pSC11.HBs using Superfect. Following a two hour incubation the cells were incubated for 2 days in MEM with 2% (v/v) FCS to allow recombination and viral replication to occur.

Wild type and recombinant viruses were released by repeated freeze/thawing of the cells (3 times in a dry ice/isopropanol bath). The virus mixture was diluted (undiluted, 10<sup>-1</sup>, 10<sup>-2</sup> 10<sup>-3</sup>) in MEM with 2% (v/v) FCS and plated out on fresh CEF monolayers. The monolayers were overlaid with 2 mL of agarose (2% (w/v) low melting point agarose mixed 1:1 with 2 x MEM containing 4% (v/v) FCS and 2 x penicillin/streptomycin). Following 48 hours incubation a further overlay of agarose containing X-gal (0.25  $\mu$ g/mL) was added. After overnight incubation blue-stained areas containing recombinant virus expressing LacZ could be identified. These were isolated by picking areas containing agarose and the underlying infected cells with Gilson P1000 pipette tips. Virus was released by freeze thawing (3 times), diluted, sonicated and re-plated as described. This procedure was repeated five times.

#### Preparation of MVA.HBs virus stock

After 5 rounds of plaque purification, two 75cm<sup>2</sup> tissue culture flasks (T-75) of CEFs were infected with the plaque-purified material. A cytopathic effect (CPE) was observed and the virus was harvested 3-days after infection. The virus was amplified further in 5 T-150 flasks, harvested and titrated. Harvested virus was stored at -70°C.

#### Bulk virus preparation

Recombinant MVA.HBs was grown on primary CEFs (ten T-150 flasks with CEFs almost confluent). Maximum CPE was visible after 3 days and the cells were harvested. Virus content was determined by titration. The material was diluted to  $1 \times 10^7$  pfu/mL in 10 mM Tris (pH 9.0).

To test the sterility of the bulk virus preparation, 200 µL of the diluted stock was inoculated into LB medium and incubated overnight.

#### Titration of the virus stock by X-gal staining

CEFs were plated into 24-well plates ( $4 \times 10^5$  cells per well) and incubated overnight to obtain the required confluency. The virus stock was diluted (10<sup>-2</sup>, 10<sup>-3</sup>, 10<sup>-4</sup>, 10<sup>-5</sup>, 10<sup>-6</sup>, 10<sup>-7</sup> and 10<sup>-8</sup>) in MEM with 2% (v/v) FCS and 100 µL aliquots were distributed into 4 wells. Following incubation for 1 hour at 37°C each well was overlaid with approximately 0.4 mL CMC overlay. Plates were incubated for 48 hours. Wells were filled with 1% (v/v) formaldehyde and the cells were fixed for 5 minutes. All liquid was then removed and the wells were washed with PBS (1 mL/well).

For one plate, the following staining solution was prepared (in this order) and 0.4 mL added to each well:

- 9.73 mL H<sub>2</sub>O
- 0.1 mL 0.5 M K<sub>3</sub>Fe(CN)<sub>6</sub>
- 0.1 mL 0.5 M K<sub>4</sub>Fe(CN)<sub>6</sub>·3H<sub>2</sub>O
- 0.02 mL 1 M MgCl<sub>2</sub>

0.05 mL 50 mg/mL X-gal in dimethylformamide

Blue spots developed after 1 hour at room temperature. The spots were counted in wells where they were well separated, taking the average of the 4 wells prepared from the same dilution. The titre was calculated as follows:

- 5      Average number of spots x dilution factor x 10 = pfu/mL

#### PCR analysis of MVA.HBs

- The absence of non-recombinant MVA in the virus stock was assessed by PCR, using two sets of primers that would distinguish between recombinant and non-recombinant virus. The PCR reactions were carried out using commercially available reagents and the primers described herein. The products of the PCR reactions were analysed by agarose gel electrophoresis followed by staining with ethidium bromide. The bands generated were compared with appropriate size markers (*Hae*III-digested  $\phi$ X174 DNA). The predicted size of the PCR fragment from non-recombinant MVA is 419 bp and the predicted size of the PCR fragment from MVA.HBs is 440 bp.
- 10

- 15      Sequencing of inserted DNA in MVA.HBs

The HBs sequence inserted at the *TK* locus of MVA was isolated by PCR using. The sequence of the PCR fragment was determined by MWG Biotech AG, Germany. The oligonucleotide primers used are listed below.

#### PCR Primers

- 20      Oligonucleotide primers used for PCR analysis of MVA.HBs

HSU2: 5'-TCCTGCGTTGATGCCTTTGTA-3'

TKU: 5'-CAATTACAGATTTCTCCGTGATAGGT-3'

TKL: 5'-TCATTTGCACTTTCTGGTTCGTA-3'

Oligonucleotide primers used for isolating the HBs antigen gene from MVA.HBs

FSEQ: 5'-GTAAAACGACGGCCAGTTTGCACGGTAAGGAAGTAGAATCAT-3'

BRSEQ: 5'-AACAGCTATGACCATGTTTCCTTGGTTTGCCATACGCTC-3'

Oligonucleotide primers used for sequencing of the HBs antigen gene in MVA.HBs

5 M13/pUC universal forward primer: 5'-GTAAAACGACGGCCAGT-3'

M13/pUC universal reverse primer: 5'-CACACAGGAAACAGCTATGACCAT-3'

III656a1: 5'-GGTCCTAGGAATCCTGATG-3'

III656a2: 5'-GGATGTTATGGGTCCTTGC-3'

## RESULTS

### 10 Construction and characterisation of plasmid pSC11.HBs

Plasmid pSC11.HBs was constructed by insertion of a *HinDIII-NsiI* fragment containing the *pre-S2* and *S* genes of HBV into the polylinker region of plasmid pSC11 (Figure 8). Plasmid pSC11.HBs therefore contains the vaccinia late/early P7.5 promoter driving expression of the inserted S antigen, and the vaccinia late promoter P11 driving expression of the *lacZ* marker gene, flanked by the left and right fragments of the vaccinia thymidine kinase (*TK*) gene.

The DNA fragments generated following digestion of pSC11 and pSC11.HBs with restriction enzymes *BamHI* and *XhoI* is shown in Figure 9.

### Construction and characterisation of MVA.HBs

#### 20 Selection and purification of recombinant MVA.HBs

A recombinant MVA.HBs virus was isolated by 5 rounds of plaque purification following infection/transfection of CEF cells with wild type MVA and pSC11.HBs. A stock of virus was purified by sucrose density centrifugation. However, further analysis of this stock indicated that it contained non-recombinant MVA in addition to recombinant MVA.HBs. A second round of plaque purification was therefore initiated using virus purified by Impfstoffwerk Dessau-Tornau GmbH (IDT,

Germany) as the starting material. Following a further 5 rounds of plaque purification, a single plaque was used to infect two T-75 flasks of CEFs. Cells were harvested and the virus was amplified further by using this material to infect five T-150 flasks. Cells were harvested and the virus titre was determined to be  $1.25 \times 10^8$  pfu/mL (total 2.5 mL).

#### Bulk virus preparation

Ten T-150 flasks were infected with the plaque-purified virus stock. Cells were harvested and the virus titre was determined to be  $2.2 \times 10^9$  pfu/mL (total 5 mL). This material was diluted to  $1 \times 10^7$  pfu/mL and its sterility confirmed by inoculation of LB medium.

#### PCR analysis

The purity of the recombinant MVA.HBs was assessed using PCR analysis. The sterile bulk virus preparation ( $1 \times 10^7$  pfu/mL) was supplied to IDT where it was used to further amplify the virus. This material was then returned to Oxon Pharmaccines for PCR analysis. Viral genomic DNA was extracted and the absence of nonrecombinant virus was confirmed (Figure 10). A band was detected in the reaction mixture containing MVA.HBs genomic DNA plus the HBs-specific primers (Figure 10, lane 2). No bands were detected in the reaction mixtures containing either genomic DNA from an irrelevant recombinant MVA (MVA.Mel3) or non-recombinant genomic DNA (Figure 10, lanes 3 and 4). A band was detected in the reaction mixture containing nonrecombinant MVA genomic DNA plus the MVA-specific primers (Figure 10, lane 8). No bands were detected in the reaction mixtures containing either MVA.HBs genomic DNA or genomic DNA from an irrelevant recombinant MVA (MVA.Mel3) (Figure 10, lanes 6 and 7).

#### Sequencing of the inserted HBsAg gene

The inserted gene in MVA.HBs was determined and was consistent with the

predicted sequence (Figure 11).

## DISCUSSION

The transfer vector pSC11.HBs was generated by insertion of a gene fragment containing the *pre-S2* and *S* sequences of HBV strain *ayw* between the left and right fragments of the vaccinia thymidine kinase (*TK*) gene present in plasmid pSC11. Plasmid pSC11 also contains the *lacZ* gene between the flanking *TK* regions. Plasmid pSC11.HBs was characterised by restriction enzyme analysis. The pattern of fragments generated, and their sizes, were consistent with the predicted pattern based on the sequence of the plasmid.

Transfecting CEF cells infected with wild-type MVA with pSC11.HBs resulted in homologous recombination across the *TK* sequences. Recombinant virus was identified by the presence of blue plaques due to the expression of *LacZ*. Recombinant virus was plaque-purified 5 times and a stock of MVA.HBs was prepared. Analysis of this stock indicated that it also contained non-recombinant MVA and a further 5 rounds of plaque purification were therefore carried out. A virus stock was produced and characterised by titration using X-gal staining (titre  $1.25 \times 10^8$  pfu/mL). A bulk virus preparation was also made. The purity of the recombinant virus was confirmed by PCR analysis.

The MVA.HBs was also characterised by sequencing the HBV gene. The sequence obtained was consistent with the predicted sequence.

Recombinant MVA.HBs contains the *pre-S2* and *S* regions of HBV strain *ayw* under control of the vaccinia P7.5 promoter. It also contains the bacterial *lacZ* marker gene under the control of the vaccinia P11 promoter. MVA is a strongly attenuated vaccinia virus strain and the recombinant MVA.HBs virus should therefore be a suitable immunisation vector for use in humans.

**Example 3 Induction of Specific CD8+ T cell Responses Against the Hepatitis B Virus Surface Antigen in BALB/c mice**

- To evaluate the ability of the pSG2.HBs and MVA.HBs immunotherapeutic to induce specific CD8+ T cell responses against the hepatitis B virus surface antigen (HBsAg), BALB/c mice were immunised intramuscularly with pSG2.HBs (50 µg) or intradermally with MVA.HBs (5 x 10<sup>6</sup> pfu). In BALB/c mice, the peptide IPQSLDSWWTSL is recognised by CD8+ T cells as the immunodominant epitope. Using this peptide, CD8+ T cells were assayed using two different methods:
- a cytotoxicity assay involving *in vitro* restimulation with peptide followed by a standard <sup>51</sup>Cr release lysis assay;
  - an ELISPOT assay to determine the number of IFN-gamma secreting peptide-specific CD8+ T cells (spot forming cells = SFC).

**MATERIALS AND METHODS**

**Cytotoxicity assay**

- Single cell suspensions of splenocytes were prepared as follows. Individual spleens were macerated and the suspension filtered through a cell strainer. The cells were pelleted and red blood cells were lysed using a hypotonic buffer. The splenocytes were resuspended in buffer and restimulated for 5-8 days with an HBsAg peptide (IPQSLDSWWTSL).
- The peptide-specific cytotoxic activity was determined using a standard <sup>51</sup>Cr release assay, in which peptide-restimulated splenocytes are tested for their ability to lyse peptide-pulsed syngeneic target cells (P815 cells). Cytotoxicity was tested on P815 cells pulsed with either the relevant HbsAg peptide (IPQSLDSWWTSL) or with an irrelevant peptide. Target cells were incubated with Na<sup>51</sup>Cr and peptides for 1 hour at 37°C. After washing, the target cells were coincubated (four hours) with effector cells at decreasing ratios of effector to target (E:T) cells. The E:T ratios tested were:- 100:1, 33:1, 11:1, 3:1 and 1:1. For determination of minimum and maximum <sup>51</sup>Cr-release, target cells were incubated



with medium alone or with 0.3% Triton-X100, a detergent that lyses the cell membranes. Release of  $^{51}\text{Cr}$  was measured in a beta counter. Percent specific lysis was determined according to the following formula:

5                    
$$\% \text{ specific lysis} = \frac{(\text{sample release} - \text{medium release})}{(\text{maximum release} - \text{medium release})}$$

#### BLISPOT assay

Microtitre plates were coated with rat anti-mouse IFN antibody and then splenocytes isolated from each immunised animal were added to the wells, with  
10 or without an HBsAg-derived peptide (IPQSLDSWWTSL). For all cell concentrations tested with the HBsAg peptide, control wells (without the HBsAg peptide) with the same number of splenocytes were included in the assay. Half a million target cells (splenocytes from naïve BALB/c mice) were added to all wells. Following incubation, splenocytes were removed and any secreted IFN was  
15 detected following incubation with a biotinylated rat anti-mouse IFN antibody followed by a streptavidin-alkaline phosphatase conjugate and subsequent colour development with BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitroblu tetrazolium). Results were expressed as the number of IFN-secreting cells (spot-forming cells; SFC) per million splenocytes. For each cell  
20 concentration tested, the background number of SFC in the relevant control wells was subtracted from the number of SFC in wells incubated with the HBsAg peptide to give the number of peptide-specific SFC/well. For each sample, the number of SFC per million splenocytes was then calculated from the wells with the highest concentration of cells (31, 000 splenocytes per well) that gave rise  
25 to 50-200 peptide-specific SFC/well, or the lowest cell concentration tested (31, 000 splenocytes per well) where all values were greater than 200 SFC/well.

## RESULTS

Groups of animals injected with four doses of pSG2.HBs, given two weeks apart, developed low, but detectable, CD8+ T cell responses as measured in a lysis assay or by an ELISPOT assay (40-100 SFC/10<sup>6</sup> splenocytes). Groups of animals

5 injected with four doses of MVA.HBs developed relatively strong CD8+ T cell responses as detected by both assays (80-150 SFC/10<sup>6</sup> splenocytes). However, all animals that were primed by two immunisations with pSG2.HBs, and boosted twice with MVA.HBs, developed very strong CD8+ T cell responses (150-250 SFC/10<sup>6</sup> splenocytes).

### 10 Cytotoxicity assay – results

Lysis of P815 target cells by *in vitro*-restimulated splenocytes pooled from five animals at a ratio of effector:target (E:T) cells of 33:1, are summarised in Table 1.

Table 1: Induction of Specific Cytolytic Responses

| Treatment group       | Day 1 (6 animals) |         | Day 2 (6 animals) |         |
|-----------------------|-------------------|---------|-------------------|---------|
|                       | Males             | Females | Males             | Females |
| 1 (control)           | 16.7              | 9.4     | 8                 | 10      |
| 2 (plasmid DNA)       | 23.5              | 16.2    | 1.5               | 0.3     |
| 3 (MVA)               | 28.4              | 27.0    | 0.4               | 41.2    |
| 4 (plasmid DNA + MVA) | 73.0              | 20.7    | 7.5               | 60.4    |

No CTL response (other than a borderline response in one male group) was

15 seen in control animals (group 1). A moderate CTL response was detected in one group of male animals and one group of female animals receiving plasmid DNA alone (group 2). Both groups of female animals but only one of the male groups receiving

MVA.HBs alone (group 3) mounted a CTL response. Similarly, both groups of female animals and only one male group receiving the DNA prime:MVA boost regimen (group

20 4) mounted a CTL response. The responses seen in two of these groups were, however, substantially higher than those seen in animals immunised with DNA or MVA

alone.

#### ELISPOT results

- No response was detected in control animals (group 1). Animals receiving plasmid DNA alone (group 2) had detectable, but low levels of SFC (generally < 100 SFC/  $10^6$  splenocytes). Immunisation with MVA.HBs alone (group 3) gave similar responses, with one group of females having a slightly higher response. In contrast, both male and female animals receiving the DNA prime:MVA boost regimen (group 4) had high levels of peptide-specific IFN- $\gamma$ -secreting T cells.

Table 2: Induction of Specific IFN- $\gamma$ -secreting T Cells

| Treatment group       | Day 1 (5 animals) |         | Day 2 (5 animals) |         |
|-----------------------|-------------------|---------|-------------------|---------|
|                       | Males             | Females | Males             | Females |
| 1 (control)           | 3                 | 13      | 3                 | 40      |
| 2 (plasmid DNA)       | 107               | 42      | 62                | 77      |
| 3 (MVA)               | 96                | 118     | 63                | 159     |
| 4 (plasmid DNA + MVA) | 245               | 262     | 255               | 169     |

- In summary, priming of BALB/c mice with plasmid pSG2.HBs and boosting with MVA.HBs resulted in the induction of both CTL responses and IFN- $\gamma$ -secreting T cells (as measured by the  $^{51}\text{Cr}$  lysis and ELISPOT assays, respectively). The prime-boost regimen induced stronger responses than immunisation with plasmid DNA alone. Administration of MVA.HBs alone resulted in similar levels of CTL but lower levels of IFN- $\gamma$ -secreting T cells, compared with the prime-boost regimen.

These results demonstrate the effective delivery and presentation, *in vivo*, of the HBsAg antigen by both the plasmid and MVA delivery systems, as well as the enhanced immunogenicity of the DNA prime:MVA boost regimen in the mouse.

**Example 4: Patient Studies - Phase I Clinical Studies of an HBV  
Immunotherapeutic in Healthy Individuals**

Two phase I studies were conducted. In the first study, 18 healthy male subjects in the United Kingdom were divided into two groups of nine (Group A and Group B).  
5 In Group A, six subjects received four injections of  $5 \times 10^7$  pfu MVA.HBs i.d. and three subjects received two placebo injections followed by two injections of  $5 \times 10^7$  pfu MVA.HBs i.d. All injections were administered at three week intervals. In Group B, six subjects received two injections of 1 mg pSG2.HBs i.m., followed by two doses of  $5 \times 10^7$  pfu MVA.HBs i.d., while the other three subjects received two placebo injections,  
10 followed by two injections of  $5 \times 10^7$  pfu MVA.HBs i.d. Injections were administered at three week intervals.

There were no significant changes seen in vital signs (e.g., blood pressure, heart rate, temperature and respiratory rate) in any subject on trial. No local side effects were seen after pSG2.HBs injection. Mild to moderate injection site reactions were seen in  
15 all subjects dosed with MVA.HBs. These reactions including erythema, swelling, flaking, and tenderness. One subject reported aching joints and tiredness two days after the first injection of MVA and one reported tingling of the tip of his tongue on the day of the second injection, both of which were considered possibly or probably related to trial drug. All other treatment-related adverse events were injection site-related.

20 Although some changes were observed in liver function tests (LFTs), in seven subjects (one on placebo and six on active treatment), only two subjects did not complete the full course of treatment due to raised LFTs. A third subject in Group A showed an increase in g-glutamyl transferase (GGT) above the normal range and a mild increase in alanine transferase (ALT) prior to receiving the second injection. Values  
25 returned to normal after this and the third injection but GGT increased to more than twice the upper limit of normal prior to the fourth injection, which was therefore not given. This subject was referred to a hepatologist, who found no abnormality other than the enzyme values. One subject (Subject 11) in Group B had GGT levels around 50% above the upper limit of normal on screening, which values increased to more than

twice the upper limit of normal after the first and second injections, accompanied by abnormal ALT values. The third and fourth doses were withheld in this subject. All values returned to normal 3 weeks post the last injection except the GGT in Subject 11 which returned to pre-dose values.

5        These changes in LFTs did not show a clear pattern or temporal relationship to trial treatment. Some subjects entered the trial with abnormal values, probably related to lifestyle, and, therefore, were probably not suitable subjects. The protocol did not prohibit alcohol intake during the trial period and the subjects were not institutionalised or tested for blood alcohol levels during the study. For Group A, the third and fourth  
10        injections and for Group B, the second and third injections spanned the Christmas/New Year period. It is possible, therefore, that increased alcohol intake may have confounded the interpretation of these LFT changes and no firm conclusion can be drawn in terms of relationship to trial treatment.

      In Group A, immunisation induced IFN-gamma-secreting HBs-specific T cell  
15        responses in two subjects who received four active MVA injections. In Group B, an HBs-specific T-cell response was seen in two subjects who received two placebo then two active MVA injections and in one subject who received two DNA then two MVA injections. The level of T cell responses was moderate and peaked seven days post-MVA inoculation. Responses against HBs-derived peptide pools correlated with  
20        detection of T cell responses against HBs antigen and HLA-A2 peptide pools. No HBs-specific antibody response was observed. All volunteers who received MVA developed very high titres of MVA-specific antibodies.

      A second phase I study was carried out in eight healthy volunteer subjects in The Gambia. Five subjects were treated with 1 mg pSG2.HBs twice. Three others were  
25        treated with  $5 \times 10^7$  pfu MVA.HBs twice. No significant abnormalities were seen in laboratory safety tests after dosing. Local side effects were similar to those seen in the first study, described above, although erythema was less noticeable, and shiny plaques were also observed in pigmented skin. Two subjects experienced itching and one subject experienced scaling of skin at the DNA injection site. All subjects experienced

local side effects including hardness, scaling and shiny plaque formation at MVA injection sites. One subject reported feeling feverish 5 hours after DNA injection and one reported headache 5 days after DNA injection. Other minor side effects were considered unrelated to trial treatment. HBs-specific immune responses were seen in 4 of 5 volunteers dosed with DNA alone and in 3 of 3 volunteers dosed with MVA alone, the size of the MVA response being approximately double that response observed for the DNA plasmid. All of these volunteers had anti-HBs antibodies present at baseline (indicating past, resolved, hepatitis B infection). There was no increase in anti-HBs antibody levels after DNA immunisation, but two of three MVA-treated volunteers showed an increase in anti-HBs after MVA immunisation. It is postulated that the greater immune response seen in the Gambian trial population relative to the U.K. volunteers was due to this prior infection.

The Phase I study has shown that two doses of 1mg pSG2.HBs i.m., followed by two doses of  $5 \times 10^7$  pfu MVA.HBs i.d., at three week intervals, or four doses of  $5 \times 10^7$  pfu MVA.HBs i.d., at three week intervals, were well tolerated in healthy volunteers.

#### **Example 5: Clinical Determination of Optimum Dosing Regimens for an HBV Immunotherapeutic Involving Plasmid and MVA Delivery**

Following on from the phase I study (described herein), three different dosage regimens were tested in patients with chronic HBV hepatitis to determine the optimum dosage regimen for treatment. The particular objectives of this study were:

- 1) to assess the tolerability of three different dosing regimens of a hepatitis immunotherapeutic in patients with HBeAg-positive, chronic hepatitis B; and
- 2) to determine the cellular immune response induced by these three dosing regimens.

## MATERIALS AND METHODS

### PART ONE - Investigation of dosing regimens:

Three different dosing regimens of pSG2.HBs and MVA.HBs were investigated in an open, non-randomised, rising-dose fashion. Treatment regimens were administered as follows:

- Group 1: Two doses of 1mg pSG2.HBs i.m., followed by two doses of  $5 \times 10^7$  pfu MVA.HBs i.d.
- Group 2: Two doses of 2mg pSG2.HBs i.m., followed by two doses of  $1.5 \times 10^8$  pfu MVA.HBs i.d.
- Group 3: Two doses of 2mg pSG2.HBs i.m., followed by two doses of  $5 \times 10^8$  pfu MVA.HBs i.d.

In each regimen, the interval between immunisations was three weeks (e.g., administration of doses at Weeks 0, 3, 6 and 9).

### PART TWO - Efficacy of dosing regimens

Fifty-four Patients were randomly assigned to one of the three treatment groups. Treatment regimens for each group were as follows:

- Group A: Two doses of 2mg pSG2.HBs i.m., followed by two doses of  $5 \times 10^8$  pfu MVA.HBs i.d., with three week intervals between doses (e.g., dosing at Weeks 0, 3, 6 and 9).
- Group B: 100 mg of lamivudine were administered daily for 14 weeks. In addition, two doses of 2mg pSG2.HBs i.m., followed by two doses of  $5 \times 10^8$  pfu MVA.HBs i.d., were administered with three week intervals between doses (e.g., dosing at Weeks 0, 3, 6 and 9). Administration of lamivudine commenced 4 weeks prior to the first immunotherapeutic dose (immunotherapeutic dosing at Weeks 4, 7, 10 and 13).

Group C: 100 mg of lamivudine were administered daily for 14 weeks.

The treatment phase visit schedule for the patients in groups A, B and C of Part 2 were as shown in Table 7.

Table 7. Dosage Regimen for Groups A, B and C.

|   |   |      |   |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |
|---|---|------|---|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|
| 5 |   | Week | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
|   | A | S    | D | v |   | D | v |   | M | v |   | M | v  |    |    |    |    | v  |    |    |    |
|   | B | S    | L |   |   |   | D | v |   | D | v |   | M  | v  |    | M  | v  |    |    |    |    |
|   | C | S    | L |   |   |   | v |   |   | v |   |   | v  |    |    |    |    | v  |    |    |    |

Key: S = Screening carried out at approximately week -14

D = pSG2.HBs immunisation (2 mg)

M = MVA.HBs immunisation ( $5 \times 10^8$  pfu)

L = Start Lamivudine therapy (100 mg/day)

10 v = Non-immunisation visit

#### Assessment of safety and tolerability

##### Definitions

An adverse event (AE) is any undesirable medical experience or change of an existing condition that occurs during or after administration of an investigational agent, whether or not it is considered related to the trial. Abnormal laboratory findings considered by the Principal Investigator to be clinically significant, e.g., those that are unusual or unusually severe for the population being studied, were considered to be adverse events. In addition, any unusual or extreme injection site reactions (such as scabbing, abscesses or ulcerations) were recorded as AEs, as were any injection site reaction that persists for more than 7 days.

A serious adverse event (SAE) is any experience that causes a significant hazard to the patient and includes any event that is fatal, life-threatening (places the patient at



immediate risk of death), and/or requires or prolongs hospitalisation, as well as any event that is significantly or permanently disabling, constitutes a (new) malignancy, or is a congenital abnormality/birth defect in the offspring of a patient who was participating in the trial at the time of conception or during the pregnancy of the mother.

5    **Assessment of injection site reactions**

Injection sites were assessed at 30 minutes (Groups A and B) or 2 hours (Groups 1, 2 and 3) after immunisation, as well as 7 days after immunisation, and 5 weeks after the final immunisation. Injection Site Reactions were separately classified according to the severity of the following indications: swelling, pain, erythema, itch and ulceration.

- 10    Injection site reactions were designated as either mild, moderate or severe based on size (erythema and swelling) or clinical judgement (itchiness, ulceration and pain). For assessment of erythema and swelling, sizes of less than 1 cm, 1-3 cm, and greater than 3 cm were designated as mild, moderate and severe, respectively.

**RESULTS -**

- 15    Eighty-seven total treatment-related adverse events (AEs) were recorded over the course of the treatment phase of the study, of which sixty-one of these events were related to the injection site (Table 3). As discussed herein, the majority of injection site reactions were comparatively mild. Furthermore, systemic adverse events were generally associated with an immune response, such as flu-like symptoms.

- 20    Only three serious adverse effects (SAEs) were reported during the 14-week course of treatment, of which one was unrelated to the treatment. The other two SAEs were incidents of elevated aminotransferase (ALT) activity, and required hospitalisation of the patient for observation. Increased ALT can be associated with viral clearance from the liver, and at least two of these SAEs are thought to be  
25    implicated in a clinical response due to the treatment program.

Table 3. Summary of Adverse Events (AEs) Following Various Treatment Regimens

|                   | Part 1        |               |               | Part 2         |                |                | Total |
|-------------------|---------------|---------------|---------------|----------------|----------------|----------------|-------|
|                   | Gp 1<br>(N=7) | Gp 2<br>(N=6) | Gp 3<br>(N=6) | Gp A<br>(N=21) | Gp B<br>(N=22) | Gp C<br>(N=11) |       |
| Total No. AEs     | 2             | 2             | 18            | 43             | 41             | 4              | 110   |
| Treatment-related | 2             | 1             | 17            | 38             | 28             | 1              | 87    |
| At injection site | 0             | 0             | 12            | 34             | 15             | N/A            | 61    |
| SAEs              | 1             | 0             | 0             | 2              | 0              | 0              | 3     |

Reactions at the injection site showed that the DNA and MVA immunotherapeutics were generally safe and well tolerated at dosages up to, and including,  $5 \times 10^8$  pfu of MVA.HBs. The majority of injection site reactions were mild (72%), and only 2% of injection sites were classified as having severe injection site reactions in this study (Table 4). Notably, a greater number of local and systemic events that were consistent with the induction of an immune response to therapy, were also observed in the group that received the highest dose. As a result, the highest dosage regimen (e.g., two doses of 2 mg pSG2.HBs followed by two doses of  $5 \times 10^8$  pfu MVA.HBs.) was chosen for use in PART TWO.

Table 4. Severity of Injection Site Reactions

|                      | Part 1        |               |               | Part 2         |                |                 |
|----------------------|---------------|---------------|---------------|----------------|----------------|-----------------|
|                      | Gp 1<br>(N=7) | Gp 2<br>(N=6) | Gp 3<br>(N=6) | Gp A<br>(N=21) | Gp B<br>(N=22) | Total<br>(N=62) |
| No. Pt with $\geq 1$ | 5             | 4             | 6             | 20             | 19             | 54 (87%)        |
| Mild                 | 9             | 11            | 8             | 33             | 32             | 204 (73%)       |
| Moderate             | 8             | 0             | 6             | 40             | 20             | 74 (25%)        |
| Severe               | 1             | 1             | 4             | 0              | 0              | 6 (2%)          |
| TOTAL                | 15            | 12            | 19            | 123            | 112            | 281             |

The predominant injection site reactions consisted of mild or moderate swelling or erythema, with lower incidences of mild itch, pain and ulceration (Table 5). The number of moderate injection site reactions decreased with the second MVA.HBs injection, consistent with the patients becoming more tolerant to the MVA vaccination (Table 6).

Collectively, the data obtained in this study indicated that the tested therapeutic vaccination regimens involving pSG2.HBs and MVA.HBs produced side effects that were generally limited to the injection site. Combination with lamivudine did not result in an increase in side effects (compare Group A and Group B in Tables 1-4). Therefore, the present invention provides a therapy for HBV that is better tolerated than currently available immunotherapeutics, such as interferon.

Table 5. Injection Site Reactions Categorized by Reaction Type

| Reaction    | Assessment | Group 1<br>(N=7) | Group 2<br>(N=6) | Group 3<br>(N=5) | Group 4<br>(N=21) | Group 5<br>(N=22) | Total<br>(N=61) |
|-------------|------------|------------------|------------------|------------------|-------------------|-------------------|-----------------|
| Erythema    | Mild       | 4                | 2                | 0                | 20                | 27                | 53              |
|             | Moderate   | 3                | 0                | 2                | 15                | 6                 | 26              |
|             | Severe     | 0                | 0                | 1                | 0                 | 0                 | 1               |
| Swelling    | Mild       | 3                | 2                | 4                | 20                | 23                | 52              |
|             | Moderate   | 1                | 0                | 2                | 14                | 7                 | 25              |
|             | Severe     | 1                | 0                | 2                | 0                 | 0                 | 3               |
| Itch        | Mild       | 0                | 1                | 0                | 14                | 15                | 30              |
|             | Moderate   | 0                | 0                | 0                | 3                 | 5                 | 8               |
|             | Severe     | 0                | 0                | 0                | 0                 | 0                 | 0               |
| Pain        | Mild       | 2                | 1                | 0                | 22                | 22                | 47              |
|             | Moderate   | 1                | 0                | 1                | 3                 | 2                 | 7               |
|             | Severe     | 0                | 1                | 1                | 0                 | 0                 | 2               |
| Vaccination | Mild       | 0                | 2                | 0                | 0                 | 0                 | 2               |
|             | Moderate   | 0                | 0                | 0                | 0                 | 0                 | 0               |
|             | Severe     | 0                | 0                | 0                | 0                 | 0                 | 0               |
| TOTAL       |            | 15               | 12               | 19               | 129               | 112               | 287             |

Table 6. Injection Site Reactions Categorized by Immunization

| Immunization | Assessment | Group 1<br>(N=7) | Group 2<br>(N=6) | Group 3<br>(N=5) | Group 4<br>(N=21) | Group 5<br>(N=22) | Total<br>(N=61) |
|--------------|------------|------------------|------------------|------------------|-------------------|-------------------|-----------------|
| PSO2-HBs     | Mild       | 0                | 0                | 0                | 0                 | 0                 | 0               |
|              | Moderate   | 0                | 0                | 0                | 0                 | 0                 | 0               |
|              | Severe     | 0                | 0                | 0                | 0                 | 0                 | 0               |
| PSO2-HBs     | Mild       | 0                | 0                | 0                | 0                 | 0                 | 0               |
|              | Moderate   | 0                | 0                | 0                | 0                 | 0                 | 0               |
|              | Severe     | 0                | 0                | 0                | 0                 | 0                 | 0               |
| HVA-HBs      | Mild       | 5                | 7                | 5                | 24                | 23                | 64              |
|              | Moderate   | 2                | 0                | 5                | 21                | 15                | 45              |
|              | Severe     | 1                | 0                | 1                | 0                 | 0                 | 2               |
| HVA-HBs      | Mild       | 0                | 1                | 2                | 20                | 15                | 38              |
|              | Moderate   | 1                | 0                | 0                | 4                 | 4                 | 9               |
|              | Severe     | 0                | 1                | 2                | 0                 | 0                 | 3               |
| TOTAL        |            | 15               | 12               | 19               | 129               | 112               | 287             |

**Example 6: Clinical Determination of the Efficacy of an HBV Immunotherapeutic Involving Plasmid and MVA Delivery Relative to a Known HBV Treatment**

Lamivudine (3TC) is a nucleoside analogue inhibitor of reverse transcriptase activity, which was initially developed as an anti-HIV agent. Lamivudine can be given orally and shows two modes of viral suppression. First, the active triphosphate metabolite mimics deoxycytidine triphosphate and is incorporated into newly synthesised HBV DNA, leading to chain termination. Second, the active form shows competitive inhibition of reverse transcriptase activity.

Studies of lamivudine in patients with chronic HBV infection have shown that treatment with lamivudine results in a rapid decrease in the plasma levels of HBV DNA. However, these levels return to baseline on cessation of therapy. Lamivudine is generally well tolerated and is licensed for the treatment of adults with chronic hepatitis B associated with HBV replication and active liver disease. One downside of extended lamivudine monotherapy is the development of mutations in the HBV genome and viral resistance.

The efficacy of the HBV immunotherapeutic of the present invention, involving DNA plasmid/MVA delivery, was compared with that of a lamivudine/therapeutic HBV immunotherapeutic combination, and treatment with lamivudine alone. The antiviral efficacy of each treatment was measured by assessing seroconversion rates, plasma HBV DNA load and levels of the liver enzymes, alanine transferase (ALT) and aspartate transferase (AST), throughout the first 14/18 weeks of treatment and at 6, 9 and 12 months after the start of treatment. Tolerability and immune response were assessed at intervals throughout the treatment period.

## MATERIALS AND METHODS

## ELISPOT assays

ELISPOT Assays were carried out by Cellular Technology Limited (CTL Laboratory LLC, 10515 Carnegie Ave., Suite 503 Cleveland OH 44106, USA ) using the following assay conditions:

|                                  |                                  |
|----------------------------------|----------------------------------|
| Antigen preparation              | Fresh                            |
| Thawing method                   | Warm + DNase                     |
| Counting method                  | Guava ViaCount®                  |
| Cell preparation                 | PBMC thawed and used immediately |
| 10 No. cells per well in ELISPOT | $3 \times 10^5$                  |
| Length of assay                  | 24 hours                         |
| Type of spot counter             | CTL Immunospot Reader            |

The following peptides were pooled and used as antigens:

|    | Antigen | Disease/Model | Antigen              | Peptide Sequence |
|----|---------|---------------|----------------------|------------------|
| 15 | HBS 1   | Hepatitis B   | PreS2 + S <i>ayw</i> | MQWNSTTFHQTLDQP  |
|    | HBS 2   | Hepatitis B   | PreS2 + S <i>ayw</i> | TFHQTLDQPRVRGLY  |
|    | HBS 3   | Hepatitis B   | PreS2 + S <i>ayw</i> | QDPRVRGLYFPAGGS  |
|    | HBS 4   | Hepatitis B   | PreS2 + S <i>ayw</i> | GLYFPAGGSSSGTVN  |
|    | HBS 5   | Hepatitis B   | PreS2 + S <i>ayw</i> | GGSSSGTVNPVLTTA  |
| 20 | HBS 6   | Hepatitis B   | PreS2 + S <i>ayw</i> | TVNPVLTTASPLSSI  |
|    | HBS 7   | Hepatitis B   | PreS2 + S <i>ayw</i> | TTASPLSSIFSRIGD  |
|    | HBS 8   | Hepatitis B   | PreS2 + S <i>ayw</i> | SSIFSRIGDPALNME  |
|    | HBS 9   | Hepatitis B   | PreS2 + S <i>ayw</i> | IGDPALNMENITSGF  |
|    | HBS 10  | Hepatitis B   | PreS2 + S <i>ayw</i> | NMENITSGFLGPLLV  |
| 25 | HBS 11  | Hepatitis B   | PreS2 + S <i>ayw</i> | SGFLGPLLVLQAGFF  |
|    | HBS 12  | Hepatitis B   | PreS2 + S <i>ayw</i> | LLVLQAGFFLLTRIL  |

|    |        |             |                      |                   |
|----|--------|-------------|----------------------|-------------------|
|    | HBS 13 | Hepatitis B | PreS2 + S <i>ayw</i> | GFFLLTRILTIPQSL   |
|    | HBS 14 | Hepatitis B | PreS2 + S <i>ayw</i> | RILTIPQSLDSWWT    |
|    | HBS 15 | Hepatitis B | PreS2 + S <i>ayw</i> | QSLDSWWTSLNFLGG   |
|    | HBS 16 | Hepatitis B | PreS2 + S <i>ayw</i> | WTSNFLGGTTVCLG    |
| 5  | HBS 17 | Hepatitis B | PreS2 + S <i>ayw</i> | LGGTTVCLGQNSQSP   |
|    | HBS 18 | Hepatitis B | PreS2 + S <i>ayw</i> | CLGQNSQSPTSNNHSP  |
|    | HBS 19 | Hepatitis B | PreS2 + S <i>ayw</i> | QSPTSNNHSPSTCPPT  |
|    | HBS 20 | Hepatitis B | PreS2 + S <i>ayw</i> | HSPTSCPPTCPGYRW   |
|    | HBS 21 | Hepatitis B | PreS2 + S <i>ayw</i> | PPTCPGYRWMCLRRF   |
| 10 | HBS 22 | Hepatitis B | PreS2 + S <i>ayw</i> | YRWMCLRRFIIIFLFI  |
|    | HBS 23 | Hepatitis B | PreS2 + S <i>ayw</i> | RRFIIIFLIFILLLCLI |
|    | HBS 24 | Hepatitis B | PreS2 + S <i>ayw</i> | LFILLLCLIFLLVLL   |
|    | HBS 25 | Hepatitis B | PreS2 + S <i>ayw</i> | CLIFLLVLLDYQGML   |
|    | HBS 26 | Hepatitis B | PreS2 + S <i>ayw</i> | VLLDYQGMLPVCPLI   |
| 15 | HBS 27 | Hepatitis B | PreS2 + S <i>ayw</i> | GMLPVCPLIPGSSTT   |
|    | HBS 28 | Hepatitis B | PreS2 + S <i>ayw</i> | PLIPGSSTTSTGPCR   |
|    | HBS 29 | Hepatitis B | PreS2 + S <i>ayw</i> | STTSTGPCRTCMTTA   |
|    | HBS 30 | Hepatitis B | PreS2 + S <i>ayw</i> | PCRTCMTTAQGTSMY   |
|    | HBS 31 | Hepatitis B | PreS2 + S <i>ayw</i> | TTAQGTSMYPSCCCT   |
| 20 | HBS 32 | Hepatitis B | PreS2 + S <i>ayw</i> | SMYPSCCCTKPSDGN   |
|    | HBS 33 | Hepatitis B | PreS2 + S <i>ayw</i> | CCTKPSDGNCTCIPI   |
|    | HBS 34 | Hepatitis B | PreS2 + S <i>ayw</i> | DGNCTCIPIPSSWAF   |
|    | HBS 35 | Hepatitis B | PreS2 + S <i>ayw</i> | IPIPSSWAFGKFLWE   |
|    | HBS 36 | Hepatitis B | PreS2 + S <i>ayw</i> | WAFGKFLWEWASARE   |
| 25 | HBS 37 | Hepatitis B | PreS2 + S <i>ayw</i> | LWEWASAREFSWLSLL  |
|    | HBS 38 | Hepatitis B | PreS2 + S <i>ayw</i> | AREFSWLSLLVPFVQW  |
|    | HBS 39 | Hepatitis B | PreS2 + S <i>ayw</i> | SLLVPFVQWFGVGLSP  |
|    | HBS 40 | Hepatitis B | PreS2 + S <i>ayw</i> | VQWFGVGLSPTVWLSV  |

|          |             |                      |                 |
|----------|-------------|----------------------|-----------------|
| HBS 41   | Hepatitis B | PreS2 + S <i>ayw</i> | LSPTVWLSVIWMMWY |
| HBS 42   | Hepatitis B | PreS2 + S <i>ayw</i> | LSVIWMMWYWGPSLY |
| HBS 43   | Hepatitis B | PreS2 + S <i>ayw</i> | MWYWGPSLYSILSPF |
| HBS 44   | Hepatitis B | PreS2 + S <i>ayw</i> | SLYSILSPFLPLLPI |
| 5 HBS 45 | Hepatitis B | PreS2 + S <i>ayw</i> | SPFLPLLPIFFCLWV |
| HBS 46   | Hepatitis B | PreS2 + S <i>ayw</i> | FLPLLPIFFCLWVYI |

The HBs series of peptides are arranged into 4 distinct pools of peptides, each containing up to 12 total peptides:

| 10 Pool No. | 1  | 2  | 3  | 4  |
|-------------|----|----|----|----|
|             | 1  | 12 | 23 | 36 |
|             | 2  | 13 | 25 | 37 |
|             | 3  | 14 | 26 | 38 |
|             | 4  | 15 | 27 | 39 |
| 15          | 5  | 16 | 28 | 40 |
|             | 6  | 17 | 29 | 41 |
|             | 7  | 18 | 30 | 42 |
|             | 8  | 19 | 31 | 43 |
|             | 9  | 20 | 32 | 44 |
| 20          | 10 | 21 | 33 | 45 |
|             | 11 | 22 | 34 | 46 |
|             |    |    | 35 |    |

The entire HbsAg protein was also used as an antigen.

25 An ELISPOT response to a peptide pool (or HbsAg protein) was considered to have occurred when the mean  $\pm$  standard deviation for the peptide pool, or HbsAg protein, was greater than the mean + 3 standard deviations of that patient's negative control.



#### Liver enzyme (ALT) assays

Liver enzyme assays were carried out by the hospital analytical laboratories at each study site, according to local procedures.

#### Viral load

5       Viral load measurements were carried out as follows:

Groups 1-3: An Amplicor HBV Monitor (Roche) was used to measure viral load, according to the manufacturer's instructions:

- Sensitivity: 200 copies/ mL
- Linear range: 1 000 to  $4 \times 10^7$  copies/mL

10       Groups A, B, C: The COBAS Taqman system (Roche) was used according to the manufacturer's instructions:

- Sensitivity: 35 copies/ mL
- Linear range: 169 –  $6.4 \times 10^8$  copies/mL

15       All viraemias above the linear range were reported as "Above maximum linear range".

#### HBeAg, HBsAg, anti-HBe and anti-HBs serotyping

Serotyping was performed using a VITROS ECI Immunodiagnostic System.

#### RESULTS: Efficacy

20       The responses to treatment for each treatment group, *i.e.*, Groups 1-3 (see Example 5), Group A (immunotherapeutic), Group B (immunotherapeutic + lamivudine) and Group C (lamivudine alone), are summarised in Table 8. Significantly, 2 out of 19 patients in Groups 1-3, and 3 out of 21 patients in Group A, seroconverted to HBe (became HBeAG negative and anti HBe positive) by week 14 (Table 9). None  
25       of the 11 patients in the lamivudine control group (Group C) had seroconverted after 14 weeks of therapy with lamivudine alone.

Table 8. Treatment Phase Summary Response

|                        | Part I<br>(n=19) | Gp A<br>(n=21) | Gp B<br>(n=22) | Gp C<br>(n=11) |
|------------------------|------------------|----------------|----------------|----------------|
| HBeAg Loss             | 4                | 5              | 3              | 1              |
| HBeAg seroconversion   | 2                | 3              | 0              | 0              |
| HBeAg Loss             | 0                | 0              | 0              | 1              |
| HBeAg seroconversion   | 0                | 0              | 0              | 0              |
| HBV DNA < 1.5 log      | 1                | 5              | 18             | 9              |
| ALT Normalized         | 4                | 1              | 4              | 2              |
| Immunological response | N/A              | 6              | 9              | 5              |

Table 8 shows that patients in each group demonstrated therapeutic responses to treatment, including drop in viral load, normalisation of liver enzyme (ALT) levels and immunological responses to HBs antigens (as determined by ELISPOT assays of CD8+ interferon-gamma secreting T cells; ELISPOT data was not available for Groups 1-3). Tables 9 and 10 show that anti-HBe seroconversion was also observed for one patient in PART ONE (Groups 1-3), 52 weeks after the start of the study. PART TWO (Groups A-C) are still currently under observation. Tables 11-14 indicate the presence or absence of various treatment responses in individual patients.

Table 9. HBeAg Clearance and anti-HBe Seroconversion

|             |                | Part 1<br>(Ops 1-3<br>combined) | Group A | Part 2<br>Group B | Group C | Total |
|-------------|----------------|---------------------------------|---------|-------------------|---------|-------|
| Week 0:     | n              | 19                              | 21      | 22                | 11      | 73    |
|             | HBeAg+         | 19                              | 21      | 22                | 11      | 73    |
| Week 14/18: | HBeAg+         | 13                              | 14      | 13                | 0       | 40    |
|             | HBeAg-         | 4 (21%)                         | 5 (24%) | 2 (14%)           | 1 (9%)  | 12    |
|             | Anti-HBe+      | 2                               | 4       | 0                 | 0       | 6     |
|             | Seroconversion | 2 (11%)                         | 3 (14%) | 0                 | 0       | 5     |
| Week 52:    | HBeAg+         | 14                              | 7       | 7                 | 1       | 29    |
|             | HBeAg-         | 2 (13%)                         | 4       | 4                 | 1       | 11    |
|             | Anti-HBe+      | 1                               | 7       | 1                 | 1       | 10    |
|             | Seroconversion | 1 (5%)                          | 7       | 1                 | 1       | 10    |

\*One patient became anti-HBe+ but did not lose HBeAg.

Table 10. HBsAg Clearance and anti-HBs Seroconversion

|             |                | Part 1<br>(Ops 1-3<br>combined) | Group A | Group B | Group C | Total |
|-------------|----------------|---------------------------------|---------|---------|---------|-------|
| Week 0:     | n              | 19                              | 21      | 22      | 11      | 73    |
|             | HBsAg+         | 19                              | 21      | 22      | 11      | 73    |
| Week 14/18: | HBsAg+         | 17                              | 18      | 16      | 0       | 51    |
|             | HBsAg-         | 0                               | 0       | 0       | 1 (9%)  | 1     |
|             | Anti-HBs+      | 1                               | 1       | 0       | 1       | 3     |
|             | Seroconversion | 0                               | 0       | 0       | 0       | 0     |
| Week 52:    | n              | 16                              | 0       | 0       | 0       | 16    |
|             | HBsAg+         | 16                              | 0       | 0       | 0       | 16    |
|             | HBsAg-         | 0                               | 0       | 0       | 0       | 0     |
|             | Anti-HBs+      | 0                               | 0       | 0       | 0       | 0     |
|             | Seroconversion | 0                               | 0       | 0       | 0       | 0     |

Table 11. Summary - Treatment Responses for Individuals from Combined Groups 1-3

| PI  | Week 14. |              |                             |             | Week 52.      |              |                             |             |
|-----|----------|--------------|-----------------------------|-------------|---------------|--------------|-----------------------------|-------------|
|     | HBeAg    | Anti<br>HBe+ | HBV DNA<br>drop<br>≥1.5 log | ALT<br>norm | HBeAg<br>loss | Anti<br>HBe+ | HBV DNA<br>drop ≥1.5<br>log | ALT<br>norm |
| 101 |          |              |                             | X           |               |              | X                           | X           |
| 102 | X        | X            | X                           | X           |               |              |                             | X           |
| 103 | X        |              |                             |             |               |              |                             |             |
| 104 |          |              |                             |             | X             |              | X                           |             |
| 107 | X        |              |                             | X           | X             | X            | X                           | X           |
| 202 | X        | X            |                             |             |               |              |                             |             |
| 304 |          |              |                             |             |               |              |                             |             |

Table 12. Summary of Treatment Responses for Individuals from Group A

| Patient | HBeAg<br>loss | Anti<br>HBe+ | HBV DNA<br>drop ≥1.5 log | ALT<br>norm | Immune<br>response |
|---------|---------------|--------------|--------------------------|-------------|--------------------|
| 403     |               |              |                          |             | X                  |
| 405     |               |              | X                        |             |                    |
| 407     | X             | X            | X                        |             | X                  |
| 408     | X             |              |                          |             |                    |
| 409     |               |              |                          | X           |                    |
| 415     | X             | X            | X                        |             |                    |
| 419     | X             |              |                          |             | X                  |
| 422     |               | X            |                          |             |                    |
| 428     |               |              |                          |             | X                  |
| 429     |               |              |                          |             | X                  |
| 429     | X             | X            | X                        |             | X                  |

Table 13. Summary of Treatment Responses for Individuals from Group B

| Patient | HBeAg loss | Anti-HBe+ | HBV DNA drop >1.5 log | ALT norm | Immune response |
|---------|------------|-----------|-----------------------|----------|-----------------|
| 501     |            |           | X                     |          | X               |
| 505     |            |           | X                     |          | X               |
| 508     | X          |           | X                     | X        | X               |
| 509     | X          |           | X                     | X        | X               |
| 510     |            |           | X                     |          | X               |
| 512     |            |           |                       | X        |                 |
| 515     |            |           |                       | X        |                 |
| 516     |            |           |                       |          | X               |
| 517     |            |           |                       |          | X               |
| 518     |            |           | X                     |          | X               |
| 519     |            |           | X                     |          | X               |
| 521     | X          |           | X                     |          |                 |

Table 14. Summary of Treatment Responses for Individuals from Group C

| Patient | HBeAg loss | Anti-HBe+ | HBV DNA drop >1.5 log | ALT norm | Immune response |
|---------|------------|-----------|-----------------------|----------|-----------------|
| 601     |            |           | X                     | X        |                 |
| 604     |            |           | X                     |          | X               |
| 605     | X          |           | X                     |          | X               |
| 606     |            |           | X                     | X        |                 |
| 607     |            |           | X                     |          | X               |
| 608     |            |           | X                     |          | X               |
| 610     |            |           | X                     |          | X               |

Observed immunological responses were classed into the following groups:

- “baseline” - an immune response (as defined above) was detected prior to commencement of treatment (i.e., week 0 for Groups 1-3 and Group A, and week 4 for Groups B and C). Said immune response subsequently was unchanged or reduced during the course of the study; “boosted” - an immune response was detected prior to commencement of treatment as discussed above, and increased with treatment over the

course of the study; "de novo" - an immune response was not present at the start of the study, but appeared following therapy. Group A (immunotherapeutic alone) included 3 baseline immunological responses, 2 boosted responses (*i.e.*, 2/5 baseline responses were boosted by the therapy) and 4 de novo responses (*i.e.*, 4/16 baseline non-  
5 responders gained an immune response following therapy) (Table 12). Group B (immunotherapeutic + lamivudine) included 3 baseline immunological responses, 4 boosted responses (*i.e.*, 4/7 baseline responses were boosted by the therapy) and 5 de novo responses (*i.e.*, 5/15 baseline non-responders gained an immune response following therapy) (Table 13). Group C (lamivudine alone) included 3 baseline  
10 immunological responses, 5 boosted responses (*i.e.*, 5/8 baseline responses were boosted by lamivudine), but no de novo responses (0/3 baseline non-responders gained an immune response following lamivudine therapy) (Table 14).

These data demonstrate that the immunotherapeutic of the present invention (*e.g.*, an HBV immunotherapeutic involving DNA plasmid and recombinant MVA  
15 delivery) is able to stimulate immune responses in previously unresponsive HBV patients. In contrast, treatment with lamivudine alone was unable to stimulate immune responses in previously unresponsive HBV patients. The immunotherapeutic of the present invention was also able to produce up to 14% seroconversion (Group A; Table 12) by a series of four injections over only 14 weeks. No seroconversion was observed  
20 over the 14 weeks of Group C (lamivudine only; Table 14). The immunotherapeutic, therefore, represents a viable approach to therapy of chronic HBV and provides further proof of the efficacy of "prime-boost" immunotherapeutics in the clinic.

**Example 7: Elevated Aminotransferase Activity that is Temporally Linked to Immunizations is Associated with Seroconversion.**

25 Two treated subjects, subject 102 from Group 1 (see Example 5 and Table 11) and subject 421 from Group A (see Example 6 and Table 12), experienced an alanine transferase (ALT) activity "flare" (*i.e.*, a significant increase in ALT activity) at approximately the same time following the second injection of pSG2.HBs plasmid

DNA during their respective treatment regimens (Figures 12 and 13). The flares resulted in very high levels of ALT activity, which required both patients to be

5 hospitalised for observation. Therefore, the detection of the flares were recorded as serious adverse events (SAEs), described in Example 5.

Increases in ALT activity appear to have been induced following the first (subject 421) or second (subject 102) injection of pSG2.HBs DNA. In both patients, ALT activity levels peaked and returned to baseline levels shortly thereafter.

0 ALT flares are often correlated with viral clearance, and both subjects 102 and 421 demonstrated seroconversion by week 14 (see Tables 11 and 12, respectively). Figures 12 and 13 also indicate that subjects 102 and 421 showed a significant loss of viral load by week 14, coinciding with the timing of the ALT flare. Therefore, in at least two subjects, immune responses against HBV appear to have been induced by  
5 injection of pSG2.HBs plasmid DNA, prior to injection of MVA.HBs. This is a surprising result, as injection of DNA alone has been generally considered to be poorly  
15 immunogenic.

#### Example 8 – Analysis of Memory T cell Immune responses by *in vitro* stimulation (IVS)

##### 10 IFN- $\gamma$ ELISPOT

*Ex vivo* IFN- $\gamma$  ELISPOT analysis provides a measure the effector T cell immune response against a specific antigen. The effector T cell immune responses determined by *ex vivo* IFN- $\gamma$  ELISPOT against the HBsAg in patients participating in Parts 1 and 2 of the clinical trial  
15 (Example 6), although satisfying the endpoint of mean  $\pm$  s.d. of the response to a peptide pool being greater than mean + 3 s.d. of a negative control, were of very low magnitude and more prevalent in patients that received treatment with lamivudine (Part 2 Groups B and C) than in patients who received heterologous PrimeBoost alone (Part 2 Group A). As shown in Table 12, only 6/11 of the Group A patients showed an effector T cell immune response.

Recent clinical studies discussed in Keating et al, (Journal of Immunology 2005, 175:5675-5680) have suggested that *ex vivo* ELISPOT responses to heterologous PrimeBoost peak at 7 days after the boosting vaccination and begin falling 14 days after the boosting vaccination. This may be due to the contraction of the effector T cell population, leaving behind a memory T cell population, which are able to proliferate and respond to future antigen challenge. The memory T cells detected by IVS ELISPOT may be evidence of a more durable, long-term immune response induced by heterologous Prime-Boost.

## 10 Materials and Methods

### IN VITRO STIMULATION

PBMC were thawed and resuspended in RN10 media (RPMI 1640 media, [Invitrogen], supplemented with 2mM L-glutamine, 50 units/mL penicillin, 50 µg/mL streptomycin and 10% heat inactivated foetal bovine serum) to a final concentration of  $4-5 \times 10^6$  cells/mL.

15

PBMC were incubated with a combined pool of all the Hepatitis B peptides described in Example 6, at a final peptide concentration of 2.5 µg/peptide/mL for 14 days. At days 3 and 7 of incubation, the cells are stimulated by addition of 20 units of IL-2 for 4 days each.

## 20 ELISPOT assays

Microtitre plates were coated with anti-IFN-gamma capture antibody (MAb 1-D1k).  $1 \times 10^5$  PBMC were added to each well, and incubated overnight with one of the four HBs peptide pools described in Example 6.

Following incubation, PBMC were removed and any secreted IFN-gamma was detected following incubation with a biotinylated anti-IFN detecting antibody (mAb 7-B6-1) followed by a streptavidin-alkaline phosphatase conjugate and subsequent colour development with BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitroblue tetrazolium). The spots in each well were counted with an AID ELISpot reader running ELISpot Version 3.1. The number of spots from the four HBs peptide pools were summed and the total as expressed as the number of IFN – gamma secreting cells (spot-forming cells; SFC) per million splenocytes.

30



## Results

After analysis by *in vitro* stimulation (IVS) followed by IFN- $\gamma$  ELISPOT assay, samples from the same patients showed a different pattern of responses to the *ex vivo* ELISPOT assay. All patients tested from Part 2 Group A (vaccine alone) of the study (Patients 405, 407, 408, 416, 419) showed an increased IFN- $\gamma$  ELISPOT response at week 10 and/or week 14 (Figure 14A). Thus, all patients in this group showed an increased response after the administration of heterologous PrimeBoost with pSG2.HBs and MVA.HBs. In contrast, none of the patients tested from Group C (Patients 605 and 607) (Figure 14C) showed an increase in the IFN- $\gamma$  ELISPOT responses during the time course, indicating that there was no marked effect after anti-viral treatment with Lamivudine only. Interestingly, patients from Group B, who received both Lamivudine treatment and heterologous PrimeBoost, exhibited a mixture of responses (Figure 14B) that were similar to those observed in Group A (Patients 509 and 517) and those in Group C (Patients 510 and 519).

Preliminary studies have indicated that the IFN- $\gamma$  ELISPOT responses observed include contributions from both CD4+ and CD8+ T cells (data not shown)

In the IVS assay, PBMC are cultured for 14 days in the presence of HBsAg antigen-derived overlapping peptides and IL-2 before the T cell immune response is determined by IFN- $\gamma$  ELISPOT. Thus, IVS assays provide a measure of antigen-specific memory T cells that proliferate on interaction with their target- antigen. Thus, the IVS assay using HBsAg provides an indication of the memory T cell immune response elicited in clinical samples. By conducting IVS using the HBsAg antigen on patient samples from clinical trial OP02/TVB/001, we have demonstrated that PrimeBoost treatment induces memory T cell immune responses against the HBsAg. These responses were evident in all patients that were tested from Group A, which received PrimeBoost immunisation only. Notably, this group also exhibited the highest level of seroconversion against the HBeAg but showed the lowest magnitude of immune responses against the HBsAg in the *ex vivo* IFN- $\gamma$  ELISPOT assays. Considered together, these results indicate that heterologous PrimeBoost immunisation elicited memory T cell responses against the HBsAg, and increased clinical effect against the disease.

All references cited herein are incorporated by reference in their entirety.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

**CLAIMS**

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO. 3, or a fragment thereof.
2. A nucleic acid molecule according to claim 1, wherein the nucleotide sequence encodes an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 3 or a fragment thereof.
3. A nucleic acid molecule according to claim 2, wherein the nucleotide sequence encodes an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO. 3 or a fragment thereof.
4. A nucleic acid molecule according to claim 1, claim 2 or claim 3, which is a recombinant DNA plasmid.
5. A nucleic acid molecule according to claim 4, which encodes the amino acid sequence of SEQ ID NO. 3.
6. A nucleic acid molecule according to any of claims 1 to 5, which is a recombinant DNA plasmid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO. 1.
7. A nucleic acid molecule according to claim 6, wherein the nucleotide sequence is at least 95% identical to SEQ ID NO: 1.
8. A nucleic acid molecule according to claim 7, wherein the nucleotide sequence is at least 98% identical to SEQ ID NO. 1.

9. A nucleic acid molecule according to claim 8, wherein the nucleotide sequence is at least 99% identical to SEQ ID NO. 1.
10. A nucleic acid molecule according to claim 9, comprising the nucleotide sequence of SEQ ID NO. 1.
11. A non-replicating or replication impaired poxvirus comprising a nucleic acid molecule according to any of claims 1 to 3.
12. A pharmaceutical composition comprising a nucleic acid molecule according to any of claims 1 to 10 or a virus according to claim 11.
13. A composition comprising a nucleic acid molecule according to any of claims 1 to 10 or a poxvirus according to claim 11 for use in a method of treatment of the human or animal body by therapy.
14. A composition according to claim 13, for use in treating hepatitis B.
15. Use of a nucleic acid molecule according to any of claims 1 to 10 or a poxvirus according to claim 11 in the manufacture of a medicament for treating hepatitis B.
16. Use according to claim 15, wherein the medicament is for inducing a *de novo* immune response against hepatitis B in an individual.
17. Use according to claim 15, wherein the medicament is for boosting a pre-existing immune response against hepatitis B in an individual.

18. Use according to claim 15, wherein the medicament induces seroconversion of one or more HBV antigens in an individual.

19. Use according to any of claims 15 to 18, wherein the medicament is for administration in a multiple of doses.

20. Use according to claim 19, wherein the medicament is for administration twice.

21. An isolated recombinant replication-deficient poxvirus comprising the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

22. A poxvirus according to claim 21, wherein the virus is a modified vaccinia virus Ankara.

23. A modified vaccinia virus Ankara comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

24. A modified vaccinia virus Ankara according to claim 23, comprising a nucleotide sequence that is at least 95% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

25. A modified vaccinia virus Ankara according to claim 24, comprising a nucleotide sequence that is at least 98% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

26. A modified vaccinia virus Ankara according to claim 25, comprising a nucleotide sequence that is at least 99% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

27. A pharmaceutical composition comprising a virus according to any of claims 21 to 26.

28. A virus according to any of claims 21 to 26 for use in treatment of the human or animal body by therapy.

29. Use of a virus according to any of claims 21 to 26 in the manufacture of a medicament for treating hepatitis B.

30. Use according to claim 29, wherein the medicament is for administration to an individual following administration of a composition according to any of claims 12 to 14.

31. A priming composition and a boosting composition for sequential administration to an individual to treat hepatitis B; wherein

the priming composition comprises a nucleic acid molecule according to any of claims 1 to 10 or a virus according to claim 11; and

the boosting composition comprises a virus according to any of claims 21 to 26.

32. Use of a priming composition and a boosting composition in the manufacture of a medicament for sequential administration to an individual to treat hepatitis B; wherein

the priming composition comprises a nucleic acid molecule according to any of claims 1 to 10 or a virus according to claim 11; and

the boosting composition comprises a virus according to any of claims 21 to 26.

33. Use of:

- a) a priming composition comprising a DNA plasmid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 4 or SEQ ID NO: 5; and
  - b) a boosting composition comprising a recombinant MVA vector comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 4 or SEQ ID NO: 5;
- in the manufacture of a medicament for inducing an immune response against hepatitis B in a subject.

34. Use according to claim 33, wherein the DNA plasmid and/or the recombinant vector comprise nucleotide sequence that is at least 95%, 98%, 99% or 100% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

35. Use according to claim 33 or claim 34, wherein the immune response comprises a memory T cell response.

36. Use according to claim 35, wherein the immune response comprises a CD8+ memory T cell response.

37. Use according to claim 35 or claim 36, wherein the immune response comprises a CD4+ memory T cell response.

38. A method of inducing an immune response against hepatitis B in a subject comprising:

- a) administering to the subject a priming composition comprising a DNA plasmid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 4 or SEQ ID NO: 5; followed by
- b) administering to the subject a boosting composition comprising a recombinant MVA vector comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

39. A method according to claim 38, wherein the DNA plasmid and/or the recombinant vector comprise nucleotide sequence that is at least 95%, 98%, 99% or 100% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

40. A method according to claim 38 or claim 39, wherein the immune response comprises a memory T cell response.

41. A method according to claim 40, wherein the immune response comprises a CD8+ memory T cell response.

42. A method according to claim 40 or claim 41, wherein the immune response comprises a CD4+ memory T cell response.

43. A kit for inducing an immune response against hepatitis B in a subject, comprising

- a) a priming composition comprising a DNA plasmid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 4 or SEQ ID NO: 5; and
- b) a boosting composition comprising a recombinant MVA vector comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

44. A kit comprising:

- (i) a priming composition comprising a nucleic acid molecule according to any of claims 1 to 10 or a virus according to claim 11;
- (ii) a boosting composition comprising a virus according to any of claims 21 to 26; and
- (iii) instructions to administer the priming composition one or more times followed by the boosting composition one or more times to an individual.




45. A kit comprising:

- (i) two doses of a priming composition, wherein the priming composition comprises a nucleic acid molecule according to claim 5;
- (ii) two doses of a boosting composition, wherein the boosting composition comprises a modified vaccinia virus Ankara comprising a nucleotide sequence encoding SEQ ID NO: 3; and
- (iii) instructions to administer the priming composition twice followed by the boosting composition twice.


46. A kit comprising:

- (i) two doses of a priming composition, wherein the priming composition comprises a nucleic acid molecule according to claim 10;
- (ii) two doses of a boosting composition, wherein the boosting composition comprises a virus according to claim 22; and
- (iii) instructions to administer the priming composition twice followed by the boosting composition twice.




Construction of Plasmid pIH. CMVe/p - CMV enhancer/promoter region; CMVe/p/I - CMV enhancer/promoter/intron region; BGHpolyA - bovine growth hormone polyadenylation signal; Amp -  $\beta$ -lactamase gene; ColE1 - *E. coli* origin of replication; Neo - neomycin resistance gene; fl - M13 origin of replication; B - *Bam*HI; H - *Hin*DIII; M - *Mlu*I; P - *Pst*I.

Figure 1




Map of plasmid pSG2. CMV-*e/p/i* - CMV enhancer/promoter/intron A region; BGHpolyA - bovine growth hormone polyadenylation signal; KanR - kanamycin resistance gene.

Figure 2



Construction of plasmid pSG2.HBs.

Figure 3



Map of plasmid pSG2.HBs.. CMV-e/p/i - CMV enhancer/promoter/intron A region; BGHpolyA - bovine growth hormone polyadenylation signal; HBs - hepatitis B surface antigen gene; KanR - kanamycin resistance gene.

Figure 4

TGTGAGTTTCTGTGTAAGTATCGCCATTTTCCAAAAGTGATTTTGGGCATACGC  
GATATCTGGCGATAGCGCTTATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGA  
CTTGGGCGATTCTGTGTGTGCGCAAATATCGCAGTTTCGATATAGGTGACAGACGATATG  
AGGCTATATCGCCGATAGAGGCGACATCAAGCTGGCACATGGCCAATGCATATCGATCT  
ATACATTGAATCAATATTGGCCATTAGCCATATTATTTCATTGGTTATATAGCATAAATC  
AATATTGGCTATTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATAT  
TGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGT  
AATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGGTTACATAACTT  
ACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAAT  
GACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGT  
ATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCC  
CCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTT  
ATGGGACTTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGA  
TGGCGTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGA  
AGTCTCCACCCCATTTGACGTCAATGGGAGTTTGTGTTTGGCACCAAATCAACGGGACTT  
TCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGT  
GGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCAT  
CCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGA  
ACGGTGCATTGGAACGCGGATTCCCGTGCCAAGAGTGACGTAAGTACCGCCTATAGAG  
TCTATAGGCCACCCCTTGGCTTCTTATGCATGCTATACTGTTTTTGGCTTGGGGTCT  
ATACACCCCGCTTCTCATGTTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGT  
TATTGACCATTATTGACCACTCCCTATTGGTGACGATACTTTCCATTACTAATCCATA  
ACATGGCTCTTTGCCACAACCTCTCTTTATTGGCTATATGCCAATACACTGTCTTCAGA  
GACTGACACGGACTCTGTATTTTACAGGATGGGGTCTCATTATTATTATTAACAATTCA  
CATATAACACACCGTCCCGAGTGCCCGCAGTTTTTTATTAAACATAACGTGGGATCT  
CCACGCGAATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGGTAGCGCGGAGCT  
TCTACATCCGAGCCCTGCTCCCATGCCTCCAGCGACTCATGGTCTGCTCGGCAGCTCCTT  
GCTCCTAACAGTGGAGGCCAGACTTAGGCACAGCACGATGCCCAACACACAGTGTGC  
CGCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGGGGAGCGGGCTTGC  
ACCGCTGACGCATTGGAAGACTTAAGGCAGCGGCAGAAGAAGATGCAGGCAGCTGAGT  
TGTTGTGTTCTGATAAGAGTCAGAGGTAACCTCCCGTTGCGGTGCTGTTAACGGTGGAGG  
GCAGTGTAGTCTGAGCAGTACTCGTTGCTGCCGCGCGGCCACCAGACATAATAGCTGA  
CAGACTAACAGACTGTTCTTTCCATGGGTCTTTCTGCAGTACCCGTCCTTGACACGA  
AGCTTGGGCCATGCAGTGGAAATCCACAACCTTCCACCAAACCTTGCAAGATCCCGAGAG  
TGAGAGGCCCTGTATTTCCTGCTGGTGGCTCCAGTTCAGGAACAGTAAACCTGTTCTG  
ACTAGTCCCTCTCCCTTATCGTCAATCTTCTCGAGGATTGGGGACCTTGGCTGAACAT  
GGAGAACATCACATCAGGATTCTTAGGACCCCTTCTCGTGTACAGGCGGGGTTTTCT  
TGTTGACAAGAATCCTCACAATACCGCAGAGTCTAGACTCGTGGTGGACTTCTCTCAAT  
TTTCTAGGGGGAACCTACCGTGTGTCTTGGCCAAAATTCGCAGTCCCCAACCTCCAATCA  
CTCACCACCTCTTGTCTCCTCAACTTGTCTGGTTATCGCTGGATGTGTCTGCGGCGTT  
TTATCATCTTCTCTTCTATCCTGCTGCTATGCCTCATCTTCTTGTGTTCTTCTGGAC  
TATCAAGGTATGTTGCCCGTTTGTCTCTAATTCAGGATCCTCAACAACCGACGCGG  
ACCATGCCGGACCTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCTCCTGTTGCT  
GTACCAAACCTTCCGACGGAAATTCACCTGTATTCCCATCCCATCATCCTGGGCTTTC  
GGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCC  
ATTTGTTTCAAGTGGTTCGTAGGGCTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGA  
TGTGGTATTGGGGGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTACCGCTGTTACCA

Figure 5A

ATTTTCTTTTGTCTTTGGGTATACATTTAAACCCCTAACAAAACAAAGAGATGGGGTTAC  
TCTCTAAATTTTATGGGTTATGTCATTGGATGTTATGGGTCCCTTGCCACAAGAACACAT  
CATACAAAAAATCAAAGAATGTTTTAGAAAACCTTCTATTAAACAGGCCCTATTGATTGGA  
AAGTATGTCAACGAATTGTGGGTCTTTTGGGTTTTGCTGCCCCTTTTACACAATGTGGT  
TATCCTGCGTTGATGCCTTTGTAGGGAATTCTGCAGATATCCATCACACTGGCGGCCGC  
TCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTACCTAAATGCTAGAGCTCGCTG  
ATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCCTCCCCCGTGC  
CTTCCCTGACCCTGGAAGGTGCCACTCCCCTGTCTTCCCTAATAAAATGAGGAAATT  
GCATCGCATTGTCTGAGTAGGTGTCACTTCTATTCTGGGGGGTGGGGTGGGGCAGGACAG  
CAAGGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG  
CTTCTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAAAT  
TCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGA  
GCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTCCAGTGGGAAACCTGTCTG  
TGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTTCGTATTGGCG  
CTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTCTGTTTCGGCTGCGGCGAGCGG  
TATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGA  
AAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGCT  
GGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTC  
AGAGGTGGCGAAACCCGACAGGACTATAAAGATACAGGCGTTTTCCCCCTGGAAGCTCC  
CTCGTGCGCTCTCTGTTCGACCTGCGCTTACCGGATACCTGTCCGCTTTCTCCC  
TTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCCGGTGTAGG  
TCGTTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTTCAGCCGACCGCTGCGCC  
TTATCCGGTAACATACGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGC  
AGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGTACAGAGTTCT  
TGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTG  
CTGAAGCCAGTTACCTTCGGAAGAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCAC  
CGCTGGTAGCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGAT  
CTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAACTCA  
CGTTAAGGGATTTTGGTCATGAACAATAAACTGTCTGCTTACATAAACAGTAATACAA  
GGGGTGTATGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTC  
AACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTGGGCAATCAGG  
TGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATG  
GCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAACTGGCTGACG  
GAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCCATGGTT  
ACTCACCCTGCGATCCCCGGGAAAACAGCATTCAGGTATTAGAAGAATATCCTGATT  
CAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTTCGATTCT  
GTTTGTAATTGTCTTTTAAACAGCGATCGCGTATTTTCGTCTCGCTCAGGCGCAATCAGG  
AATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTG  
TTGAACAAGTCTGGAAAGAAATGCATAAGCTTTTGCCATTCTCACCGGATTCAGTCGTC  
ACTCATGGTGATTTCTCACTTGATAACCTTATTTTGGACGAGGGGAAATTAATAGGTTG  
TATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGA  
ACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTTCAAAAATATGGTATT  
GATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAATC  
AGAATTGGTTAATTGGTTGTAACTGGCAGAGCATTACGCTGA

Figure 5B


AAGCTTGGGCGCATCGAGTGGHRTTCCACAACCTTCCACCAACTCTGCARGATCCAGGA  
 M Q W N S T T F H Q T L O D P R  
 GTGAGAGCCCTGTATTCCCTGCTGCTGGCTCCAGTTTCAGGAACGTAAACCCCTGTTCT  
 V R G L Y F P A C G S S S G T V N P V L  
 GACTACTGCCCTCTCCCTTATCGTCAATCTTCTCGAGGATTTGGGGACCCCTGGCGCTGAACA  
 T T A S P L S S I F S R I G D E A L N  
 TGGAGAACATCACATCAGGATTCCTAGGACCCCTTCTCTGTTACAGGCGCGGCTTTTTC  
 H E N I T S G F L G P L L V L Q A G F F  
 TTGTTGACAGAATCCTCACATACCCGAGAGTCTAGACTCGTGGTGGCACTTCTCTCAA  
 L L T R I L T I P Q S L D S W N T S L N  
 TTTCTAGGGGGCACTACCGTGTGTCTTGGCCAAATTCGCGAGTCCCCCAACCTCCCACTC  
 F L G G T T V C L G Q W S Q S P T S N  
 ACTCACCAACCTCTTGTCTCTCAACTGTCTCTGGTTATCGGTGGAGTGTGTCTGCGGCGCT  
 E S P T S C P P T C P G Y R W M C L R R  
 TTATCACTCTCCCTCTTCACTCTGCTGCTATGCCCTCACTTCTTGTGTGGTCTCTTGGAA  
 F I I F L I L L C L I F L L V E L D  
 CTATCAGGTATGTTGCCCGTTTGTCTCTATTCAGGATCTCTACCAACCAAGCAGCGG  
 Y Q G H L P V C P L I P G S S T T S T  
 GACCATGCCCGAGCTTCATGACTACTGCTCAGGAACCTCTATGATATCCCTCCTGTGTC  
 G P C R T C M T T A Q G T S M Y P S C C  
 TGATCCAAACCTTCCGACGGAAATTCGCACTGTATTCCTCCATCCCAICATCTGGGGCTTT  
 C T K P S D G N C T C I P I P S S W A F  
 CGGAAATTCCTATGSGGAGTGGGCGCTCAGCCGCTTCTCTCTGCGTCACTTTACTAGTGC  
 C X F L W E W A S A R F S W L S L L V  
 CATTTGTTCACTGCTTCGTAGGGCTTTCCGCCCACTGTTTGGCTTTCACTTATATGAGTG  
 P F V Q W F V G L S P T V W L S V I W M  
 ATGTGCTATTTGGGGGCCAAGTCTGTACAGCACTCTTCACTCCCTTTTACCGCTGTIACC  
 M W Y W C P S L Y S I L S P F L P L L P  
 AATTTTCTTTTGTCTTTGGSTRIACATTAAACCCCTAACAAACCAAGAGATGGCGTTA  
 I F F C L W V Y I \*

**Figure 6A**




CCTCTTAATTTTATGGGTTAIGTCATTGGATGTTATGGGTCCTTGGCACAAGAACACA  
TCATACAAAATTCRAAGRAIGFTTTAGAAACTTCTATTAACAGGCCTATTGATTGG  
AAAGTAIGTCACGAATTGIGGGTCTTTTGGGTTTTGCTGCCCCCTTTACACAAIGTGG  
TTATCCTGCGTTGATGCTTTTGTAGGGAATTC

Figure 6B




Lane 1:  $\lambda$ HinDIII marker  
 Lane 2: Uncut pSG2.HBs  
 Lane 3: *Bam*HI cut pSG2.HBs  
 Lane 4: *Xho*I cut pSG2.HBs  
 Lane 5: Uncut pSG2.HBs  
 Lane 6: *Bam*HI cut pSG2.HBs  
 Lane 7: *Xho*I cut pSG2.HBs  
 Lane 8:  $\phi$ X174 *Hae*III marker

Figure 7



Map of plasmid pSC11.HBs. TKL - thymidine kinase left fragment; TKR - thymidine kinase right fragment; P11 - vaccinia P11 promoter; P7.5 - vaccinia P7.5 promoter; HBs - HBsAg gene.

Figure 8



Lanes  
 1  $\lambda$  DNA/HindIII marker  
 2 pSC11.HBs BamHI  
 3 pSC11.HBs XhoI  
 4 pSC11 BamHI  
 5 pSC11 XhoI  
 6  $\phi$ X174 DNA/HaeIII marker

Figure 9



Lane 1:  $\phi$ X174 *HaeIII* marker  
 Lane 2: MVA.HBs genomic DNA  
 Lane 3: MVA.Mel3 genomic DNA  
 Lane 4: Wild type MVA genomic DNA  
 Lane 5: Water  
 Lane 6: MVA.HBs genomic DNA  
 Lane 7: MVA.Mel3 genomic DNA  
 Lane 8: Wild type MVA genomic DNA  
 Lane 9: Water

Figure 10

Expected sequence GTAAACGAGGGCCAGTTTGACGGTAAGGAAGTAGAATCATAAAGAACAGTGACGGATCCAGCTTGGGCCAT  
 Actual Sequence GTAAACGAGGGCCAGTTTGACGGTAAGGAAGTAGAATCATAAAGAACAGTGACGGATCCAGCTTGGGCCAT  
  
 GCAGTGGAAATTCACAAACCTTCCACCACCTCTGCAAGATCCAGAGTGAGAGGCTGTATTTCCCTGCTGGTCCAGTTCAGGAACAG  
 GCAGTGGAAATTCACAAACCTTCCACCACCTCTGCAAGATCCAGAGTGAGAGGCTGTATTTCCCTGCTGGTCCAGTTCAGGAACAG  
 TAAACCTGTTCTGACTACTGCTCTCCCTTATCGTCAATCTTCTCGAGGATTGGGACCCCTGCGCTGAACATGGAGAACATCACATCAGGA  
 TAAACCTGTTCTGACTACTGCTCTCCCTTATCGTCAATCTTCTCGAGGATTGGGACCCCTGCGCTGAACATGGAGAACATCACATCAGGA  
 TTCTAGGACCCCTTCTCGTGTACAGGCGGGGTTTTCTTGTGACAAGAAATCCTCACATACCGCAGAGTCTAGACTCGTGGTGGACTTC  
 TTCTAGGACCCCTTCTCGTGTACAGGCGGGGTTTTCTTGTGACAAGAAATCCTCACATACCGCAGAGTCTAGACTCGTGGTGGACTTC  
 TCTCAATTTCTAGGGGGAACCTACCGTGTGCTTGGCCAAAATTCGCAGTCCCAACCTCCAACTCACTCAACCAACCTCTTGTCTCCAACCTT  
 TCTCAATTTCTAGGGGGAACCTACCGTGTGCTTGGCCAAAATTCGCAGTCCCAACCTCCAACTCACTCAACCAACCTCTTGTCTCCAACCTT  
 GTCCTGGTTATCGCTGGATGTGCTCGGGCGTTTATCATCTTCTCATCCTGCTGCTATGCCCTCATCTTCTTGTGGTCTTCTGGAC  
 GTCCTGGTTATCGCTGGATGTGCTCGGGCGTTTATCATCTTCTCATCCTGCTGCTATGCCCTCATCTTCTTGTGGTCTTCTGGAC  
 TATCAAGGTATGTTGCCCGTTTGTCTCTAATTCAGGATCCTCAACAACAGCAGCGGGACCATGCCGGACCTGCATGACTACTGCTCAAGG  
 TATCAAGGTATGTTGCCCGTTTGTCTCTAATTCAGGATCCTCAACAACAGCAGCGGGACCATGCCGGACCTGCATGACTACTGCTCAAGG  
 AACCTCTATGATCCCTCCTGTTGCTGTACCAAAACCTTCGGACGGAAATTCACCTGTATTCCTATCCCATCCCATCATCCTGGGCTTTCGGAAAAT  
 AACCTCTATGATCCCTCCTGTTGCTGTACCAAAACCTTCGGACGGAAATTCACCTGTATTCCTATCCCATCCCATCATCCTGGGCTTTCGGAAAAT  
 TCCTATGGAGTGGGCTCAGCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTGTTCAAGTGGTTCGTAGGGCTTTCCTCCCACTGTTTGG  
 TCCTATGGAGTGGGCTCAGCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTGTTCAAGTGGTTCGTAGGGCTTTCCTCCCACTGTTTGG  
 CTTTCAGTTATATGGATGATGTTGTTGGGGCCCAAGTCTGTACAGCATCTTGAGTCCCTTTTACCCTGTTACCAATTTCTTTTGTCT  
 CTTTCAGTTATATGGATGATGTTGTTGGGGCCCAAGTCTGTACAGCATCTTGAGTCCCTTTTACCCTGTTACCAATTTCTTTTGTCT  
 TTGGGTATACATTTAAACCCTAACAAAACAAAGAGATGGGTTACTCTTAAATTTTATGGGTTATGTCATTGGATGTTATGGGTCCTTGCC  
 TTGGGTATACATTTAAACCCTAACAAAACAAAGAGATGGGTTACTCTTAAATTTTATGGGTTATGTCATTGGATGTTATGGGTCCTTGCC  
 ACAAGAACACATCATACAAAAATCAAGAATGTTTTAGAAAACCTTCCATTACAGGCCCTATTGATTGAAAAGTATGTCAACGAATTGTGG  
 ACAAGAACACATCATACAAAAATCAAGAATGTTTTAGAAAACCTTCCATTACAGGCCCTATTGATTGAAAAGTATGTCAACGAATTGTGG  
 GTCCTTTGGGTTTTGCTGCCCTTTTACACAATGTGGTTATCCTCGGTTGATGCCCTTTGTAGGAAATTCGTGAGCGTATGCGCAACGAAGG  
 GTCCTTTGGGTTTTGCTGCCCTTTTACACAATGTGGTTATCCTCGGTTGATGCCCTTTGTAGGAAATTCGTGAGCGTATGCGCAACGAAGG  
 AACATGGTCATAGCTGTT  
 AACATGGTCATAGCTGTT

Figure 11




Figure 12




Figure 13






Figure 14 A




Figure 14 B




Figure 14 C

## - Group summed responses




Figure 14 D

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/001902

## A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K14/02 C12N15/85 C12N15/863 A61K48/00 A61K39/285

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, Sequence Search, EMBL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                         | Relevant to claim No. |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X         | WO 99/41383 A (MAXYGEN, INC)<br>19 August 1999 (1999-08-19)<br>figure 17                                                                                                                                                                                                                                                   | 1-5,<br>11-20         |
| X         | CHOW YEN-HUNG ET AL: "Improvement of<br>hepatitis B virus DNA vaccines by plasmids<br>coexpressing hepatitis B surface antigen<br>and interleukin-2"<br>JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY<br>FOR MICROBIOLOGY, US,<br>vol. 71, no. 1, 1997, pages 169-178,<br>XP002176596<br>ISSN: 0022-538X<br>the whole document | 1-5,<br>11-20         |
| X         | CN 1 324 661 A (SECOND MILITARY MEDICAL<br>UNIV., PLA) 5 December 2001 (2001-12-05)<br>the whole document                                                                                                                                                                                                                  | 1-5,<br>11-20         |
| -/-       |                                                                                                                                                                                                                                                                                                                            |                       |



Further documents are listed in the continuation of Box C.



See patent family annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

15 September 2006

Date of mailing of the international search report

04/10/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Kools, Patrick

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/001902

| C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |                                                                                                                                                                                                                                                                                                                                  |                       |
|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Category*                                            | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                               | Relevant to claim No. |
| A                                                    | WOODBERRY TONIA ET AL: "Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAR 2003, vol. 170, no. 5, 1 March 2003 (2003-03-01), pages 2599-2604, XP002399069 ISSN: 0022-1767 the whole document                                                 | 1-46                  |
| A                                                    | VUOLA JENNI M ET AL: "Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JAN 2005, vol. 174, no. 1, 1 January 2005 (2005-01-01), pages 449-455, XP002399070 ISSN: 0022-1767 the whole document | 1-46                  |
| P,X                                                  | HUTCHINGS CLAIRE L ET AL: "Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JUL 2005, vol. 175, no. 1, 1 July 2005 (2005-07-01), pages 599-606, XP002399071 ISSN: 0022-1767 the whole document           | 1-46                  |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2006/001902

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 15-20 and 29-42 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-5 complete and 12-20 and 31, 32 partial

Isolated nucleic acid molecules comprising a polynucleotide encoding the polypeptide having Seq ID No 3, or those polynucleotides having at least 90% identity. Pharmaceutical compositions comprising said polynucleotides and further compositions and uses involving said polynucleotides.

---

2. claims: 1-5 partial, 6-10 completely, and 12-20, 31-46 partially

As for subject 1, now for plasmids comprising said polynucleotides and nucleic acids being a recombinant plasmid having Seq ID No 1 and sequences having at least 90% identity. Further, compositions and medical uses of compositions comprising said polynucleotides. Vaccination methods using said polynucleotides and kits comprising said polynucleotides.

---

3. claims: 1-5 partial, 11 complete, 12-20 partial, 21-30 complete, and 31-46 partial

As for subject 1, now for non-replicating or replication impaired poxviruses. Compositions comprising said viruses and uses of said compositions. Vaccination methods using said viruses and kits comprising said viruses.

---



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/001902

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---|---------------------|----------------------------|---------------------|
| WO 9941383                                | A | 19-08-1999          | AU 3289199 A               | 30-08-1999          |
|                                           |   |                     | CA 2320958 A1              | 19-08-1999          |
|                                           |   |                     | EP 1054973 A1              | 29-11-2000          |
|                                           |   |                     | JP 2002507393 T            | 12-03-2002          |
| CN 1324661                                | A | 05-12-2001          | NONE                       |                     |